| Drug |
cytarabine |
431 |
2014 |
| Drug |
cyclophosphamide |
424 |
2014 |
| Other |
laboratory biomarker analysis |
329 |
2014 |
| Drug |
methotrexate |
236 |
2014 |
| Drug |
fludarabine phosphate |
192 |
2018 |
| Drug |
rituximab |
192 |
2013 |
| Drug |
fludarabine |
178 |
2014 |
| Drug |
etoposide |
169 |
2014 |
| Procedure |
peripheral blood stem cell transplantation |
155 |
2017 |
| Drug |
busulfan |
147 |
2014 |
| Drug |
dexamethasone |
145 |
2011 |
| Biological |
filgrastim |
138 |
2016 |
| Other |
pharmacological study |
130 |
2014 |
| Drug |
mycophenolate mofetil |
117 |
2014 |
| Drug |
azacitidine |
116 |
2016 |
| Drug |
tacrolimus |
112 |
2014 |
| Drug |
idarubicin |
107 |
2014 |
| Drug |
cyclosporine |
105 |
2010 |
| Drug |
decitabine |
100 |
2014 |
| Drug |
venetoclax |
99 |
2014 |
| Procedure |
allogeneic hematopoietic stem cell transplantation |
98 |
2014 |
| Drug |
vincristine sulfate |
94 |
2010 |
| Procedure |
allogeneic bone marrow transplantation |
91 |
2010 |
| Drug |
daunorubicin hydrochloride |
89 |
2014 |
| Radiation |
radiotherapy |
84 |
2018 |
| Drug |
mercaptopurine |
82 |
2018 |
| Radiation |
total-body irradiation |
82 |
2017 |
| Drug |
dasatinib |
80 |
2009 |
| Drug |
prednisone |
80 |
2010 |
| Drug |
melphalan |
76 |
2017 |
| Drug |
clofarabine |
74 |
2010 |
| Drug |
ibrutinib |
70 |
2013 |
| Drug |
lenalidomide |
69 |
2014 |
| Drug |
vincristine |
69 |
2018 |
| Drug |
daunorubicin |
64 |
2016 |
| Biological |
anti-thymocyte globulin |
59 |
2010 |
| Drug |
leucovorin calcium |
58 |
2014 |
| Drug |
mitoxantrone hydrochloride |
58 |
2016 |
| Drug |
pegaspargase |
54 |
2018 |
| placebo |
placebo |
54 |
2017 |
| Drug |
imatinib mesylate |
53 |
2018 |
| Drug |
asparaginase |
52 |
2009 |
| Drug |
doxorubicin hydrochloride |
52 |
2014 |
| Drug |
gemtuzumab ozogamicin |
48 |
2008 |
| Biological |
alemtuzumab |
47 |
2009 |
| Drug |
g-csf |
47 |
2014 |
| Drug |
nilotinib |
47 |
2015 |
| Other |
quality-of-life assessment |
46 |
2009 |
| Drug |
thioguanine |
45 |
2010 |
| Drug |
methylprednisolone |
44 |
2010 |
| Drug |
mitoxantrone |
44 |
2014 |
| Drug |
bortezomib |
43 |
2018 |
| Drug |
obinutuzumab |
43 |
2014 |
| Biological |
sargramostim |
42 |
2011 |
| Drug |
doxorubicin |
41 |
2018 |
| Drug |
bendamustine |
38 |
2014 |
| Drug |
ofatumumab |
37 |
2010 |
| Other |
questionnaire administration |
37 |
2009 |
| Drug |
thiotepa |
37 |
2019 |
| Drug |
imatinib |
35 |
2014 |
| Drug |
sirolimus |
34 |
2017 |
| Biological |
blinatumomab |
32 |
2017 |
| Biological |
therapeutic allogeneic lymphocytes |
32 |
2013 |
| Drug |
cladribine |
31 |
2016 |
| Procedure |
umbilical cord blood transplantation |
31 |
2012 |
| Drug |
vorinostat |
31 |
2014 |
| Biological |
aldesleukin |
29 |
2014 |
| Drug |
therapeutic hydrocortisone |
29 |
2010 |
| Drug |
arsenic trioxide |
28 |
2011 |
| Drug |
ara-c |
26 |
2008 |
| Procedure |
nonmyeloablative allogeneic hematopoietic stem cell transplantation |
26 |
2009 |
| Drug |
ifosfamide |
25 |
2011 |
| Radiation |
total body irradiation |
23 |
2018 |
| Drug |
mesna |
22 |
2011 |
| Drug |
prednisolone |
21 |
2018 |
| Drug |
chemotherapy |
20 |
2018 |
| Drug |
chlorambucil |
20 |
2014 |
| Other |
flow cytometry |
20 |
2010 |
| Drug |
pentostatin |
19 |
2010 |
| Drug |
midostaurin |
18 |
2018 |
| Drug |
ruxolitinib |
18 |
2018 |
| Drug |
tipifarnib |
18 |
2011 |
| Biological |
nivolumab |
17 |
2014 |
| Drug |
sorafenib |
17 |
2009 |
| Drug |
gilteritinib |
16 |
2014 |
| Drug |
nelarabine |
16 |
2019 |
| Biological |
recombinant interferon alfa |
16 |
2005 |
| Drug |
topotecan hydrochloride |
16 |
2007 |
| Drug |
alvocidib |
15 |
2018 |
| Biological |
inotuzumab ozogamicin |
15 |
2018 |
| Drug |
ponatinib |
15 |
2019 |
| Procedure |
autologous bone marrow transplantation |
14 |
2006 |
| Drug |
carboplatin |
14 |
2014 |
| Drug |
idelalisib |
14 |
2014 |
| Biological |
pegfilgrastim |
14 |
2018 |
| Drug |
pevonedistat |
14 |
2018 |
| Drug |
quizartinib |
14 |
2019 |
| Drug |
tretinoin |
14 |
2011 |
| Drug |
acalabrutinib |
13 |
2014 |
| Procedure |
autologous hematopoietic stem cell transplantation |
13 |
2018 |
| Drug |
hydrocortisone |
13 |
2017 |
| Procedure |
stem cell transplantation |
13 |
2009 |
| Procedure |
bone marrow ablation with stem cell support |
12 |
2006 |
| Drug |
bosutinib |
12 |
2016 |
| Drug |
carmustine |
12 |
2009 |
| Drug |
cpx-351 |
12 |
2014 |
| Drug |
pembrolizumab |
12 |
2018 |
| Radiation |
total body irradiation (tbi) |
12 |
2018 |
| Drug |
allopurinol |
11 |
2012 |
| Drug |
everolimus |
11 |
2009 |
| Drug |
liposome-encapsulated daunorubicin-cytarabine |
11 |
2014 |
| Drug |
panobinostat |
11 |
2009 |
| Drug |
peg-asparaginase |
11 |
2017 |
| Drug |
plerixafor |
11 |
2010 |
| Genetic |
polymerase chain reaction |
11 |
2008 |
| Drug |
6-mercaptopurine |
10 |
2018 |
| Procedure |
allogeneic stem cell transplantation |
10 |
2013 |
| Procedure |
biopsy |
10 |
2011 |
| Procedure |
bone marrow transplantation |
10 |
2007 |
| Genetic |
cytogenetic analysis |
10 |
2010 |
| Biological |
ipilimumab |
10 |
2019 |
| Drug |
selinexor |
10 |
2014 |
| Drug |
sorafenib tosylate |
10 |
2011 |
| Drug |
thymoglobulin |
10 |
2011 |
| Drug |
bendamustine hydrochloride |
9 |
2010 |
| Biological |
bevacizumab |
9 |
2008 |
| Procedure |
bone marrow aspiration |
9 |
2018 |
| Procedure |
in vitro-treated bone marrow transplantation |
9 |
2005 |
| Procedure |
in vitro-treated peripheral blood stem cell transplantation |
9 |
2010 |
| Drug |
leucovorin |
9 |
2019 |
| Radiation |
low-let photon therapy |
9 |
1999 |
| Procedure |
stem cell transplant |
9 |
2017 |
| Drug |
treosulfan |
9 |
2014 |
| Drug |
vindesine |
9 |
2018 |
| Drug |
bryostatin 1 |
8 |
2004 |
| Other |
educational intervention |
8 |
2017 |
| Genetic |
fluorescence in situ hybridization |
8 |
2010 |
| Genetic |
gene expression analysis |
8 |
2008 |
| Drug |
hydroxyurea |
8 |
2016 |
| Drug |
l-asparaginase |
8 |
2009 |
| Procedure |
leukapheresis |
8 |
2015 |
| Genetic |
mutation analysis |
8 |
2008 |
| Drug |
romidepsin |
8 |
2009 |
| Drug |
ruxolitinib phosphate |
8 |
2014 |
| Drug |
thalidomide |
8 |
2006 |
| Drug |
adriamycin |
7 |
2018 |
| Drug |
all-trans retinoic acid |
7 |
2016 |
| Drug |
atg |
7 |
2016 |
| Drug |
brentuximab vedotin |
7 |
2012 |
| Drug |
carfilzomib |
7 |
2014 |
| Device |
clinimacs |
7 |
2018 |
| Drug |
cytosine arabinoside |
7 |
2013 |
| Procedure |
donor lymphocyte infusion |
7 |
2017 |
| Other |
exercise |
7 |
2014 |
| Biological |
granulocyte colony-stimulating factor |
7 |
2017 |
| Procedure |
hematopoietic cell transplantation |
7 |
2019 |
| Drug |
il-2 |
7 |
2016 |
| Drug |
laromustine |
7 |
2009 |
| Radiation |
low-let cobalt-60 gamma ray therapy |
7 |
1999 |
| Biological |
nk cells |
7 |
2014 |
| Drug |
pci-32765 |
7 |
2009 |
| Biological |
stem cell infusion |
7 |
2011 |
| Drug |
tanespimycin |
7 |
2005 |
| Radiation |
tbi |
7 |
2019 |
| Drug |
temozolomide |
7 |
2014 |
| Radiation |
total marrow irradiation |
7 |
2014 |
| Drug |
valproic acid |
7 |
2019 |
| Drug |
abt-199 |
6 |
2013 |
| Drug |
ac220 |
6 |
2011 |
| Drug |
all-trans retinoic acid (atra) |
6 |
2010 |
| Drug |
amsacrine |
6 |
2009 |
| Drug |
atezolizumab |
6 |
2015 |
| Drug |
atra |
6 |
2009 |
| Drug |
azacytidine |
6 |
2019 |
| Drug |
belinostat |
6 |
2018 |
| Procedure |
care |
6 |
2008 |
| Biological |
daratumumab |
6 |
2017 |
| Biological |
donor lymphocytes |
6 |
2016 |
| Drug |
eltrombopag |
6 |
2010 |
| Drug |
entinostat |
6 |
2010 |
| Biological |
graft-versus-tumor induction therapy |
6 |
2007 |
| Drug |
guadecitabine |
6 |
2016 |
| Radiation |
iodine i 131 monoclonal antibody bc8 |
6 |
2008 |
| Drug |
kg |
6 |
2016 |
| Biological |
oblimersen sodium |
6 |
2004 |
| Drug |
omacetaxine mepesuccinate |
6 |
2007 |
| Biological |
palifermin |
6 |
2010 |
| Procedure |
psychosocial assessment |
6 |
2008 |
| Procedure |
psychosocial assessment/care |
6 |
2008 |
| Other |
questionnaire |
6 |
2016 |
| Procedure |
standard follow-up care |
6 |
2010 |
| Drug |
temsirolimus |
6 |
2011 |
| Drug |
ublituximab |
6 |
2019 |
| Drug |
vosaroxin |
6 |
2016 |
| Biological |
NA |
5 |
2019 |
| Drug |
alisertib |
5 |
2009 |
| Drug |
asparaginase erwinia chrysanthemi |
5 |
2019 |
| Drug |
azd1152 |
5 |
2009 |
| Other |
blood sample |
5 |
2014 |
| Biological |
cart-19 |
5 |
2012 |
| Drug |
clofarabine (iv formulation) |
5 |
2006 |
| Drug |
dexrazoxane hydrochloride |
5 |
2010 |
| Biological |
dli |
5 |
2014 |
| Drug |
duvelisib |
5 |
2018 |
| Drug |
enasidenib |
5 |
2018 |
| Drug |
epoetin alfa |
5 |
2006 |
| Drug |
erwinase |
5 |
2014 |
| Drug |
etoposide phosphate |
5 |
2010 |
| Behavioral |
exercise intervention |
5 |
2013 |
| Drug |
gleevec |
5 |
2010 |
| Drug |
graspa |
5 |
2017 |
| Procedure |
hematopoietic stem cell transplantation |
5 |
2016 |
| Drug |
hydrocortisone sodium succinate |
5 |
2016 |
| Other |
immunologic technique |
5 |
2007 |
| Radiation |
intensity-modulated radiation therapy |
5 |
2020 |
| Drug |
isotretinoin |
5 |
2009 |
| Biological |
lintuzumab |
5 |
2006 |
| Radiation |
low-let electron therapy |
5 |
1999 |
| Drug |
mycophenolate mofetil (mmf) |
5 |
2018 |
| Biological |
natural killer cell therapy |
5 |
2014 |
| Drug |
palbociclib |
5 |
2014 |
| Other |
pharmacogenomic studies |
5 |
2010 |
| Drug |
posaconazole |
5 |
2018 |
| Drug |
rapamycin |
5 |
2008 |
| Biological |
therapeutic autologous lymphocytes |
5 |
2005 |
| Drug |
tocilizumab |
5 |
2018 |
| Drug |
topotecan |
5 |
2019 |
| Drug |
triapine |
5 |
2006 |
| Drug |
valspodar |
5 |
2000 |
| Drug |
velcade |
5 |
2014 |
| Drug |
veliparib |
5 |
2011 |
| Drug |
vp16 |
5 |
2013 |
| Drug |
5-azacitidine |
4 |
2018 |
| Drug |
5-azacytidine |
4 |
2010 |
| Drug |
7-hydroxystaurosporine |
4 |
2006 |
| Drug |
abt-263 |
4 |
2009 |
| Drug |
ag-221 |
4 |
2019 |
| Drug |
akt inhibitor mk2206 |
4 |
2011 |
| Drug |
antibodies |
4 |
2005 |
| Drug |
antithymocyte globulin |
4 |
2015 |
| Drug |
ap1903 |
4 |
2017 |
| Drug |
astx727 |
4 |
2017 |
| Procedure |
autologous stem cell transplantation |
4 |
2013 |
| Drug |
busulfan (bu) |
4 |
2018 |
| Drug |
campath-1h |
4 |
2007 |
| Biological |
cd19 car-t cells |
4 |
2020 |
| Drug |
chidamide |
4 |
2018 |
| Biological |
chimeric antigen receptor t-cell therapy |
4 |
2018 |
| Other |
clinical observation |
4 |
2014 |
| Procedure |
cord blood infusion |
4 |
2011 |
| Drug |
cyclophosphamide (cy) |
4 |
2018 |
| Drug |
cytarabine (ara-c) |
4 |
2006 |
| Drug |
dinaciclib |
4 |
2018 |
| Biological |
donor lymphocyte infusion (dli) |
4 |
2019 |
| Procedure |
double-unit umbilical cord blood transplantation |
4 |
2010 |
| Drug |
enasidenib mesylate |
4 |
2019 |
| Biological |
filgrastim-sndz |
4 |
2008 |
| Drug |
gemcitabine hydrochloride |
4 |
2006 |
| Drug |
glasdegib |
4 |
2017 |
| Biological |
gm-csf |
4 |
2009 |
| Biological |
gvhd prophylaxis |
4 |
2009 |
| Drug |
hqp1351 |
4 |
2019 |
| Procedure |
hsct |
4 |
2017 |
| Drug |
low dose cytarabine |
4 |
2013 |
| Drug |
mgcd0103 |
4 |
2007 |
| Drug |
mylotarg |
4 |
2011 |
| Biological |
nk cell infusion |
4 |
2016 |
| Drug |
oxaliplatin |
4 |
2019 |
| Drug |
paclitaxel |
4 |
1999 |
| Drug |
perifosine |
4 |
2009 |
| Procedure |
peripheral blood stem cell transplant |
4 |
2019 |
| Other |
pharmacokinetic study |
4 |
2018 |
| Genetic |
polymorphism analysis |
4 |
2008 |
| Drug |
ponatinib hydrochloride |
4 |
2018 |
| Drug |
rasburicase |
4 |
2007 |
| Drug |
sapacitabine |
4 |
2011 |
| Drug |
sl-401 |
4 |
2014 |
| Drug |
sunitinib malate |
4 |
2016 |
| Drug |
tgr-1202 |
4 |
2017 |
| Drug |
umbralisib |
4 |
2019 |
| Drug |
vm26 |
4 |
2005 |
| Drug |
volasertib |
4 |
2014 |
| Drug |
zanubrutinib |
4 |
2017 |
| Drug |
6-thioguanine |
3 |
2005 |
| Drug |
abl001 |
3 |
2014 |
| Drug |
acetaminophen |
3 |
2019 |
| Drug |
ag-120 |
3 |
2019 |
| Biological |
alt-803 |
3 |
2013 |
| Drug |
amifostine trihydrate |
3 |
1999 |
| Biological |
anti-cd19 |
3 |
2019 |
| Drug |
apr-246 |
3 |
2019 |
| Drug |
aprepitant |
3 |
2009 |
| Drug |
arac |
3 |
2014 |
| Device |
arm1 |
3 |
2019 |
| Procedure |
assessment of therapy complications |
3 |
2008 |
| Drug |
azacitadine |
3 |
2014 |
| Other |
best supportive care |
3 |
2011 |
| Drug |
bexarotene |
3 |
2009 |
| Drug |
bl-8040 |
3 |
2015 |
| Procedure |
blood draw |
3 |
2013 |
| Procedure |
bone marrow biopsy |
3 |
2015 |
| Drug |
campath |
3 |
2007 |
| Drug |
caspofungin acetate |
3 |
2011 |
| Drug |
cc-486 |
3 |
2014 |
| Biological |
cd123 car-t cells |
3 |
2019 |
| Biological |
cd19 |
3 |
2018 |
| Other |
cd34 |
3 |
2012 |
| Biological |
cd8 |
3 |
2017 |
| Drug |
cediranib maleate |
3 |
2007 |
| Procedure |
cns irradiation |
3 |
2005 |
| Procedure |
computed tomography |
3 |
2017 |
| Biological |
control |
3 |
2016 |
| Other |
counseling intervention |
3 |
2008 |
| Drug |
cpi-613 |
3 |
2013 |
| Drug |
crenolanib besylate |
3 |
2015 |
| Drug |
cusatuzumab |
3 |
2019 |
| Drug |
cy |
3 |
2018 |
| Drug |
cyclosporine a |
3 |
2013 |
| Biological |
daclizumab |
3 |
2000 |
| Drug |
darbepoetin alfa |
3 |
2008 |
| Drug |
daunomycin |
3 |
2005 |
| Drug |
decitabine (5-aza-2’deoxycytidine) |
3 |
2002 |
| Drug |
dexamethasone / prednisolone |
3 |
2005 |
| Drug |
dexrazoxane |
3 |
2017 |
| Other |
diagnostic laboratory biomarker analysis |
3 |
2010 |
| Genetic |
dna methylation analysis |
3 |
2009 |
| Drug |
eltrombopag olamine |
3 |
2009 |
| Drug |
erwinia asparaginase |
3 |
2017 |
| Biological |
etanercept |
3 |
2006 |
| Drug |
fcr |
3 |
2009 |
| Drug |
fludarabine monophosphate |
3 |
2014 |
| Drug |
forodesine hydrochloride (bcx-1777) |
3 |
2006 |
| Drug |
gemcitabine |
3 |
2017 |
| Drug |
glivec |
3 |
2013 |
| Drug |
granulocyte colony-stimulating factor (g-csf) |
3 |
2018 |
| Biological |
gti-2040 |
3 |
2007 |
| Drug |
idasanutlin |
3 |
2016 |
| Drug |
imatinib mesylate (gleevec) |
3 |
2004 |
| Drug |
interleukin-2 |
3 |
2011 |
| Procedure |
intrathecal injection |
3 |
2018 |
| Biological |
kte-x19 |
3 |
2018 |
| Biological |
kw-0761 |
3 |
2010 |
| Drug |
lbh589 |
3 |
2007 |
| Drug |
lenalidomide/dexamethasone |
3 |
2010 |
| Drug |
m^2 |
3 |
2015 |
| Procedure |
management of therapy complications |
3 |
2008 |
| Drug |
mbg453 |
3 |
2017 |
| Drug |
melphalan hydrochloride |
3 |
2017 |
| Drug |
methotrexate (mtx) |
3 |
2009 |
| Drug |
milademetan |
3 |
2014 |
| Device |
miltenyi biotec clinimacs |
3 |
2005 |
| Drug |
mtx |
3 |
2014 |
| Biological |
multi-peptide cmv-modified vaccinia ankara vaccine |
3 |
2018 |
| Drug |
ocv-501 |
3 |
2013 |
| Drug |
ondansetron |
3 |
2009 |
| Drug |
oral azacitidine |
3 |
2012 |
| Biological |
peripheral blood lymphocyte therapy |
3 |
2006 |
| Drug |
pf-04449913 |
3 |
2013 |
| Drug |
pioglitazone |
3 |
2016 |
| Drug |
poly iclc |
3 |
2012 |
| Procedure |
positron emission tomography |
3 |
2015 |
| Genetic |
protein expression analysis |
3 |
2008 |
| Drug |
radotinib |
3 |
2018 |
| Genetic |
reverse transcriptase-polymerase chain reaction |
3 |
2009 |
| Drug |
revlimid |
3 |
2010 |
| Drug |
ribavirin |
3 |
2010 |
| Drug |
rimiducid |
3 |
2018 |
| Drug |
rituxan] |
3 |
2013 |
| Drug |
rituximab [mabthera |
3 |
2013 |
| Drug |
rituximab [mabthera/rituxan] |
3 |
2013 |
| Drug |
sodium phenylbutyrate |
3 |
2000 |
| Drug |
standard chemotherapy |
3 |
2017 |
| Drug |
trametinib |
3 |
2013 |
| Drug |
vemurafenib |
3 |
2018 |
| Drug |
vidaza |
3 |
2014 |
| Dietary Supplement |
vitamin c |
3 |
2018 |
| Dietary Supplement |
vitamin d |
3 |
2017 |
| Drug |
voriconazole |
3 |
2015 |
| Drug |
vp-16 |
3 |
2014 |
| Genetic |
western blotting |
3 |
2010 |
| Drug |
15) |
2 |
2008 |
| Biological |
20 mg |
2 |
2010 |
| Radiation |
3-dimensional conformal radiation therapy |
2 |
2005 |
| Drug |
6,8-bis(benzylthio)octanoic acid |
2 |
2014 |
| Procedure |
ablative allogeneic hematopoietic cell transplantation |
2 |
2005 |
| Drug |
aclarubicin |
2 |
2017 |
| Biological |
allogeneic hematopoietic stem cell transplant |
2 |
2012 |
| Drug |
amd3100 |
2 |
2007 |
| Dietary Supplement |
american ginseng |
2 |
2008 |
| Drug |
aminopterin |
2 |
1999 |
| Biological |
anti-cd19 car-t |
2 |
2017 |
| Biological |
anti-cd22-car-transduced t cells |
2 |
2016 |
| Drug |
anti-thymocyte globulin (rabbit) |
2 |
2016 |
| Biological |
apolizumab |
2 |
2004 |
| Drug |
at-101 |
2 |
2006 |
| Biological |
atir101 |
2 |
2016 |
| Drug |
atorvastatin |
2 |
2011 |
| Procedure |
autologous-allogeneic tandem hematopoietic stem cell transplantation |
2 |
2009 |
| Other |
autologous transplantation |
2 |
2012 |
| Drug |
avelumab |
2 |
2016 |
| Drug |
aza |
2 |
2014 |
| Biological |
basiliximab |
2 |
2009 |
| Drug |
beclomethasone dipropionate |
2 |
2007 |
| Behavioral |
behavioral techniques |
2 |
2016 |
| Drug |
bi 836826 |
2 |
2016 |
| Drug |
bi 836858 |
2 |
2015 |
| Biological |
bind19 |
2 |
2017 |
| Other |
biological samples |
2 |
2016 |
| Biological |
biological therapy |
2 |
2013 |
| Procedure |
biospecimen collection |
2 |
2017 |
| Biological |
bl22 immunotoxin |
2 |
2005 |
| Behavioral |
body composition |
2 |
2007 |
| Procedure |
bone marrow aspiration/biopsy |
2 |
2016 |
| Biological |
bpx-501 t cells |
2 |
2017 |
| Drug |
br |
2 |
2009 |
| Other |
buccal swab |
2 |
2014 |
| Drug |
cabozantinib |
2 |
2019 |
| Drug |
calaspargase pegol |
2 |
2018 |
| Drug |
cc-292 |
2 |
2012 |
| Biological |
cd19 car t cells |
2 |
2013 |
| Biological |
cd20 |
2 |
2018 |
| Biological |
cd22 car-t cells |
2 |
2018 |
| Biological |
cd38 |
2 |
2019 |
| Biological |
cd56 |
2 |
2011 |
| Procedure |
chemotherapy, intrathecal chemotherapy, steroid therapy |
2 |
2005 |
| Drug |
chemotherapy/antibodies |
2 |
2005 |
| Drug |
chlorambucil, tablets |
2 |
2013 |
| Dietary Supplement |
cholecalciferol |
2 |
2014 |
| Drug |
cirmtuzumab |
2 |
2016 |
| Drug |
copanlisib |
2 |
2019 |
| Other |
cord blood transplantation |
2 |
2005 |
| Other |
correlative studies |
2 |
2013 |
| Procedure |
cranial irradiation |
2 |
2013 |
| Drug |
crenolanib |
2 |
2015 |
| Device |
ct-scan |
2 |
2014 |
| Biological |
ctl019 |
2 |
2017 |
| Drug |
cwp232291 |
2 |
2017 |
| Drug |
cx-01 |
2 |
2016 |
| Drug |
cyclophosphamide (ctx) |
2 |
2009 |
| Drug |
cyclophosphamide 50mg |
2 |
2020 |
| Drug |
cyclosporin a |
2 |
2015 |
| Drug |
cytarabine hydrochloride |
2 |
2019 |
| Drug |
cytoxan |
2 |
2019 |
| Drug |
dasatinib (bms-354825) |
2 |
2006 |
| Other |
database |
2 |
2007 |
| Biological |
dc vaccine |
2 |
2015 |
| Biological |
dcp-001 |
2 |
2018 |
| Biological |
dec-205 |
2 |
2017 |
| Biological |
dec-205/ny-eso-1 fusion protein cdx-1401 |
2 |
2017 |
| Drug |
decitabine (dacogen) |
2 |
2008 |
| Drug |
dfp-10917 |
2 |
2019 |
| Behavioral |
dietary intervention |
2 |
2016 |
| Drug |
diphenhydramine |
2 |
2019 |
| Drug |
docetaxel |
2 |
1999 |
| Drug |
dolastatin 10 |
2 |
1999 |
| Biological |
donor natural killer cell infusion |
2 |
2013 |
| Biological |
dose level 1 |
2 |
2004 |
| Biological |
dose level 2 |
2 |
2004 |
| Drug |
doxil |
2 |
2012 |
| Biological |
dt2219arl |
2 |
2009 |
| Drug |
dtrm-555 |
2 |
2020 |
| Biological |
durvalumab |
2 |
2016 |
| Drug |
elacytarabine |
2 |
2010 |
| Drug |
entospletinib |
2 |
2016 |
| Other |
enzyme-linked immunosorbent assay |
2 |
2011 |
| Biological |
epratuzumab |
2 |
2009 |
| Drug |
epz-5676 |
2 |
2012 |
| Drug |
erlotinib |
2 |
2010 |
| Biological |
ex vivo-expanded cord blood progenitor cell infusion |
2 |
2012 |
| Procedure |
fatigue assessment |
2 |
2008 |
| Procedure |
fatigue assessment/management |
2 |
2008 |
| Drug |
fenretinide |
2 |
2010 |
| Diagnostic Test |
fish |
2 |
2018 |
| Diagnostic Test |
flow-mrd |
2 |
2018 |
| Diagnostic Test |
flow immunophenotyping |
2 |
2018 |
| Drug |
fluconazole |
2 |
2019 |
| Drug |
fluorouracil |
2 |
2019 |
| Drug |
ga101 |
2 |
2014 |
| Drug |
ganciclovir |
2 |
2008 |
| Drug |
gemtuzumab ozogamicin (go) |
2 |
2017 |
| Genetic |
gene rearrangement analysis |
2 |
2007 |
| Drug |
gleevecâ® |
2 |
2009 |
| Drug |
gm-csf (sargramostim) |
2 |
2009 |
| Biological |
gm-k562 cell vaccine |
2 |
2006 |
| Biological |
graft versus host disease prophylaxis |
2 |
2005 |
| Biological |
graft versus host disease prophylaxis/therapy |
2 |
2005 |
| Biological |
haploidentical stem cell transplantation |
2 |
2017 |
| Procedure |
hematopoietic stem cell transplant |
2 |
2005 |
| Procedure |
high dose chemotherapy then autologous hematopoietic cell transplant |
2 |
2005 |
| Drug |
high dose cytarabine |
2 |
2018 |
| Drug |
histamine dihydrochloride |
2 |
1999 |
| Combination Product |
hma |
2 |
2013 |
| Drug |
homoharringtonine |
2 |
2020 |
| Biological |
hsc835 |
2 |
2013 |
| Biological |
hucart19 |
2 |
2019 |
| Biological |
human myeloid progenitor cells |
2 |
2009 |
| Drug |
idarubicine |
2 |
2011 |
| Biological |
il-15 |
2 |
2015 |
| Drug |
imatinib mesylate 400 mg |
2 |
2005 |
| Drug |
imgn632 |
2 |
2017 |
| Drug |
imtox-25 |
2 |
2011 |
| Biological |
indium in 111 anti-cd45 monoclonal antibody bc8 |
2 |
2011 |
| Other |
informational intervention |
2 |
2008 |
| Drug |
interferon |
2 |
2006 |
| Other |
internet-based intervention |
2 |
2008 |
| Drug |
intrathecal chemotherapy |
2 |
2011 |
| Drug |
intrathecal triple therapy |
2 |
2017 |
| Drug |
ipi-145 |
2 |
2013 |
| Drug |
irinotecan hydrochloride |
2 |
2003 |
| Drug |
isavuconazole |
2 |
2017 |
| Biological |
isf35 |
2 |
2008 |
| Drug |
itacitinib |
2 |
2018 |
| Combination Product |
itmha |
2 |
2017 |
| Drug |
ivosidenib |
2 |
2018 |
| Drug |
ixabepilone |
2 |
2003 |
| Drug |
ixazomib |
2 |
2014 |
| Diagnostic Test |
karyotyping |
2 |
2018 |
| Biological |
kg tru-016 |
2 |
2010 |
| Drug |
ldac |
2 |
2009 |
| Drug |
lde225 |
2 |
2013 |
| Drug |
lestaurtinib |
2 |
2007 |
| Drug |
liposomal annamycin |
2 |
2017 |
| Drug |
liposomal cytarabine-daunorubicin cpx-351 |
2 |
2013 |
| Drug |
liposomal daunorubicin |
2 |
2019 |
| Drug |
liposomal daunorubicin citrate |
2 |
2000 |
| Drug |
lithium carbonate |
2 |
2013 |
| Drug |
lmb-2 |
2 |
2009 |
| Biological |
lmb-2 immunotoxin |
2 |
2004 |
| Drug |
lodac (low dose cytarabine) |
2 |
2015 |
| Drug |
low dose ara-c (ldac) |
2 |
2012 |
| Radiation |
lymphoid irradiation |
2 |
2017 |
| Drug |
m2 |
2 |
2011 |
| Procedure |
management |
2 |
2008 |
| Other |
mass spectrometry |
2 |
2012 |
| Drug |
mbu |
2 |
2018 |
| Drug |
mbu/cy |
2 |
2018 |
| Drug |
mbu/cy/atg |
2 |
2018 |
| Drug |
mec (mitoxantrone, etoposide, cytarabine) |
2 |
2015 |
| Other |
medical chart review |
2 |
2009 |
| Biological |
mem-enriched t-lymphocytes |
2 |
2014 |
| Biological |
membrane-bound interleukin-21-expanded haploidentical natural killer cells |
2 |
2019 |
| Drug |
mercaptopurine tablet |
2 |
2008 |
| Drug |
metformin |
2 |
2011 |
| Drug |
micafungin |
2 |
2010 |
| Genetic |
microarray analysis |
2 |
2007 |
| Drug |
mln4924 |
2 |
2013 |
| Drug |
mln9708 |
2 |
2014 |
| Drug |
mmf |
2 |
2016 |
| Biological |
modified t cells |
2 |
2011 |
| Drug |
montanide isa 51 vg |
2 |
2012 |
| Drug |
motexafin gadolinium |
2 |
2006 |
| Drug |
mycofenolate mofetil |
2 |
2009 |
| Biological |
natural killer cell infusion |
2 |
2012 |
| Drug |
navitoclax |
2 |
2017 |
| Genetic |
ngs |
2 |
2018 |
| Drug |
nicordâ® |
2 |
2010 |
| Drug |
nintedanib |
2 |
2018 |
| Biological |
ny-eso-1 fusion protein cdx-1401 |
2 |
2017 |
| Other |
observation |
2 |
2018 |
| Drug |
on 01910.na |
2 |
2009 |
| Drug |
onc201 |
2 |
2019 |
| Other |
palliative care |
2 |
2017 |
| Drug |
peg-l-asparaginase |
2 |
2009 |
| Biological |
peripheral blood stem cell |
2 |
2019 |
| Other |
peripheral blood stem cell infusion |
2 |
2007 |
| Other |
pharmacodynamic studies |
2 |
2010 |
| Other |
pharmacogenomic study |
2 |
2014 |
| Drug |
pinometostat |
2 |
2018 |
| Drug |
pkc412 |
2 |
2010 |
| placebo |
placebo to match idelalisib |
2 |
2012 |
| Drug |
plx3397 |
2 |
2011 |
| Biological |
pneumococcal 13-valent conjugate vaccine |
2 |
2014 |
| Drug |
pomalidomide |
2 |
2014 |
| Drug |
pracinostat |
2 |
2013 |
| Drug |
pravastatin |
2 |
2015 |
| Drug |
pravastatin sodium |
2 |
2013 |
| Drug |
preparative regimen |
2 |
2011 |
| Biological |
pretargeted radioimmunotherapy |
2 |
2017 |
| Biological |
rabbit atg |
2 |
2016 |
| Drug |
rasburicase (sr29142) |
2 |
2005 |
| Drug |
recombinant asparaginase |
2 |
2009 |
| Biological |
recombinant flt3 ligand |
2 |
2000 |
| Biological |
recombinant interleukin-12 |
2 |
1999 |
| Drug |
rhil-15 |
2 |
2018 |
| Drug |
sargramostim (gm-csf) |
2 |
2006 |
| Drug |
selumetinib |
2 |
2007 |
| Drug |
sgn-cd33a |
2 |
2013 |
| Drug |
sitagliptin |
2 |
2009 |
| Other |
skin biopsy |
2 |
2014 |
| Drug |
solu-medrol |
2 |
2011 |
| Other |
standard care |
2 |
2017 |
| Other |
standard leukemia care |
2 |
2017 |
| Drug |
supportive care |
2 |
2013 |
| Genetic |
t-cell infusion |
2 |
2012 |
| Biological |
t cell-depleted hematopoietic stem cell transplantation |
2 |
2009 |
| Drug |
talazoparib |
2 |
2014 |
| Behavioral |
telephone-based intervention |
2 |
2019 |
| Drug |
teniposide |
2 |
2009 |
| Biological |
therapeutic immune globulin |
2 |
2008 |
| Biological |
therapy |
2 |
2005 |
| Drug |
tirabrutinib |
2 |
2016 |
| Radiation |
tomotherapy |
2 |
2007 |
| Drug |
tosedostat |
2 |
2012 |
| Radiation |
total-body irradiation (tbi) |
2 |
2009 |
| Radiation |
total marrow |
2 |
2017 |
| Radiation |
total marrow/lymphoid irradiation |
2 |
2017 |
| Drug |
tranylcypromine |
2 |
2016 |
| Drug |
treatment choice |
2 |
2016 |
| Biological |
trivalent influenza vaccine |
2 |
2015 |
| Biological |
ucart19 |
2 |
2016 |
| Biological |
umbilical cord blood |
2 |
2013 |
| Drug |
uproleselan |
2 |
2018 |
| Drug |
valganciclovir |
2 |
2010 |
| Drug |
vincristine liposomal |
2 |
2018 |
| Drug |
vyxeos |
2 |
2019 |
| Procedure |
white blood cell transfusion |
2 |
2009 |
| Biological |
wt1 peptide vaccine |
2 |
2010 |
| Radiation |
yttrium y 90 anti-cd45 monoclonal antibody bc8 |
2 |
2011 |
| Radiation |
yttrium y 90 epratuzumab |
2 |
1999 |
| Drug |
zosuquidar |
2 |
2005 |
| Drug |
- rituximab |
1 |
2014 |
| Drug |
-1 |
1 |
2016 |
| Drug |
-4 |
1 |
2016 |
| Drug |
-5 |
1 |
2016 |
| Biological |
-enriched |
1 |
2019 |
| Drug |
“prophylactic” delayed activated donor lymphocyte infusion |
1 |
2006 |
| Drug |
“prophylactic” delayed adli |
1 |
2006 |
| Procedure |
(clinimacs) t-cell depleted pbsc transplant |
1 |
2010 |
| Drug |
)xk469 |
1 |
2004 |
| Biological |
10 mg |
1 |
2012 |
| Biological |
10 mg/kg tru-016 / rituximab |
1 |
2012 |
| Drug |
111in ibritumomab |
1 |
2011 |
| Drug |
15 mg |
1 |
2010 |
| Drug |
15 mg/kg tru-016/bendamustine |
1 |
2010 |
| Drug |
17-n-allylamino-17-demethoxygeldanamycin |
1 |
2006 |
| Drug |
17-n-allylamino-17-demethoxygeldanamycin/bortezomib |
1 |
2006 |
| Drug |
18f flt |
1 |
2011 |
| Drug |
2’-f-ara-deoxyuridine |
1 |
2008 |
| Drug |
2-chlorodeoxyadenosine (cda) daily |
1 |
1999 |
| Drug |
2-chlorodeoxyadenosine weekly |
1 |
1999 |
| Biological |
20-car vector-transduced t cells |
1 |
2017 |
| Biological |
20 mg/kg tru-016 / rituximab |
1 |
2012 |
| Drug |
20 mg/kg tru-016/bendamustine |
1 |
2010 |
| Biological |
22 |
1 |
2018 |
| Biological |
22-car vector-transduced t cells |
1 |
2017 |
| Biological |
22 car t cells |
1 |
2017 |
| Drug |
2cda |
1 |
2014 |
| Drug |
2cda //- rituximab |
1 |
2014 |
| Device |
3’-deoxy-3’-[18f]fluorothymidine |
1 |
2009 |
| Drug |
3 day thiarabine |
1 |
2010 |
| Drug |
3 scheme): daunorubicin, cytarabine |
1 |
2009 |
| Drug |
3, |
1 |
2016 |
| Drug |
300 mg oral azacitidine |
1 |
2012 |
| Drug |
4 |
1 |
2016 |
| Biological |
4scar-cd22 |
1 |
2019 |
| Biological |
4scar-cd22/cd123/cd38/cd10/cd20/tslpr |
1 |
2019 |
| Drug |
5-azacytidine (5-aza) |
1 |
2006 |
| Drug |
5-fluoro-2-deoxycytidine |
1 |
2009 |
| Drug |
5 azacytidine |
1 |
2009 |
| Drug |
5 azacytidine - valproic acid- retinoic acid |
1 |
2006 |
| Drug |
5 day thiarabine |
1 |
2010 |
| Drug |
5ac |
1 |
2011 |
| Drug |
6-mercaptopurine (6-mp) |
1 |
2005 |
| Drug |
6-mercaptopurine. |
1 |
2018 |
| Drug |
6-mp |
1 |
2009 |
| Drug |
6-mp (6-mercaptopurine) |
1 |
2013 |
| Drug |
6 mercaptopurine |
1 |
2009 |
| Drug |
6mp |
1 |
2014 |
| Drug |
6mpfixed |
1 |
2008 |
| Drug |
6mpindividualized |
1 |
2008 |
| Drug |
7-hydroxystaurosporine (ucn-01) |
1 |
2000 |
| Drug |
8-chloro-adenosine |
1 |
2008 |
| Drug |
8-chloroadenosine |
1 |
2015 |
| Drug |
8-matched unrelated donors |
1 |
2012 |
| Drug |
800 mg |
1 |
2007 |
| Drug |
9-aminocamptothecin (9-ac) |
1 |
2005 |
| Drug |
90y ibritumomabtiuxetan |
1 |
2011 |
| Biological |
ab-110 |
1 |
2018 |
| Drug |
abatacept |
1 |
2009 |
| Drug |
abbv-744 |
1 |
2017 |
| Drug |
abiraterone |
1 |
2019 |
| Drug |
abl001 / nilotinib |
1 |
2014 |
| Drug |
abl001/dasatinib |
1 |
2014 |
| Drug |
abl001/imatinib |
1 |
2014 |
| Procedure |
ablative allogeneic hematopoietic cell transplant |
1 |
2005 |
| Drug |
abt-348 |
1 |
2010 |
| Drug |
abt-348/azacitidine |
1 |
2010 |
| Drug |
acadesine |
1 |
2007 |
| Drug |
acalabrutinib (acp-196) |
1 |
2016 |
| Drug |
acalabrutinib 100 mg oral capsule |
1 |
2019 |
| Biological |
acellular pertussis vaccine adsorbed |
1 |
2015 |
| Drug |
aclacinomycin, cytarabine |
1 |
2017 |
| Drug |
acp-196 |
1 |
2015 |
| Drug |
acp-319 |
1 |
2014 |
| Biological |
activated |
1 |
2014 |
| Biological |
activated/expanded natural killer cells (nkaes) |
1 |
2014 |
| Other |
active comparator |
1 |
2016 |
| Drug |
active comparator (no fludarabine) |
1 |
2009 |
| Device |
active tdcs |
1 |
2019 |
| Behavioral |
activity |
1 |
2016 |
| Other |
activity monitor |
1 |
2019 |
| Behavioral |
activity/exercise intervention |
1 |
2016 |
| Drug |
actonel (risedronate) |
1 |
2007 |
| Other |
acute lymphobastic leukemia (all) treatment options |
1 |
2015 |
| Drug |
acy-1215 |
1 |
2016 |
| Drug |
acyclovir |
1 |
2003 |
| Biological |
adct-602 |
1 |
2018 |
| Behavioral |
adherence-encouraging interventions - group meeting |
1 |
2013 |
| Behavioral |
adherence-encouraging interventions - individual meetings |
1 |
2013 |
| Behavioral |
adherence-encouraging interventions - monthly phone calls |
1 |
2013 |
| Behavioral |
adherence aids |
1 |
2017 |
| Procedure |
adjuvant therapy |
1 |
2005 |
| Drug |
administration of azd6738 |
1 |
2013 |
| Device |
administration of hyperbaric oxygen |
1 |
2014 |
| Biological |
adult differentiated autologous t-cells |
1 |
2017 |
| Other |
aerobic capacity |
1 |
2008 |
| Behavioral |
aerobic exercises |
1 |
2017 |
| Drug |
afatinib |
1 |
2019 |
| Drug |
ag-013736 (axitinib) |
1 |
2003 |
| Drug |
ag-120 (baml-16-001-s16) |
1 |
2016 |
| Drug |
ag-120 (ivosidenib) with azacitidine |
1 |
2017 |
| Drug |
ag-221 (baml-16-001-s3) |
1 |
2016 |
| Drug |
aida |
1 |
2007 |
| Drug |
alemtuzumab (campath 1h) associated to g-csf |
1 |
2008 |
| Drug |
alemtuzumab (mabcampath) |
1 |
2005 |
| Biological |
alemtuzumab i.v. |
1 |
2008 |
| Biological |
alemtuzumab s.c. |
1 |
2008 |
| Drug |
alemtuzumab/fludarabine |
1 |
2005 |
| Drug |
alentuzumab |
1 |
2006 |
| Drug |
all-trans-retinoid acid |
1 |
2005 |
| Drug |
all-trans retinoid acid |
1 |
2005 |
| Drug |
all-transretinoic acid |
1 |
2017 |
| Drug |
all trans retinoic acid (vesanoid) |
1 |
2009 |
| Biological |
allodepleted t cells |
1 |
2008 |
| Procedure |
allogeneic blood |
1 |
2005 |
| Procedure |
allogeneic blood stem cell transplant |
1 |
2009 |
| Procedure |
allogeneic blood/bone marrow transplantation |
1 |
2005 |
| Procedure |
allogeneic bone marrow |
1 |
2002 |
| Procedure |
allogeneic bone marrow transplant |
1 |
1999 |
| Biological |
allogeneic cart-19 |
1 |
2016 |
| Biological |
allogeneic cd123car-cd28-cd3zeta-egfrt-expressing t-lymphocytes |
1 |
2014 |
| Biological |
allogeneic cd34 |
1 |
2019 |
| Biological |
allogeneic cd34-positive enriched peripheral blood stem cells |
1 |
2019 |
| Biological |
allogeneic cd34/-enriched/cd45ra-depleted pbscs |
1 |
2019 |
| Biological |
allogeneic cd56-positive cd3-negative natural killer cells |
1 |
2013 |
| Procedure |
allogeneic cell transplantation |
1 |
2003 |
| Biological |
allogeneic cytomegalovirus-specific cytotoxic t lymphocytes |
1 |
2011 |
| Biological |
allogeneic epstein-barr virus-specific cytotoxic t lymphocytes |
1 |
2000 |
| Procedure |
allogeneic hct |
1 |
2002 |
| Procedure |
allogeneic hematopoietic stem-cell-transplantation |
1 |
2009 |
| Procedure |
allogeneic hematopoietic stem cell transplant (allo-hsct) |
1 |
2019 |
| Procedure |
allogeneic hematopoietic stem cell transplantation (hsct) |
1 |
2013 |
| Biological |
allogeneic hematopoietic stem cell transplantation (naive t cell-depleted pbsc) |
1 |
2018 |
| Biological |
allogeneic hematopoietic stem cell transplantation (unmanipulated t cell replete bm) |
1 |
2018 |
| Other |
allogeneic hla-identical sibling transplantation |
1 |
2012 |
| Other |
allogeneic matched related |
1 |
2012 |
| Other |
allogeneic matched related/unrelated donor transplant. |
1 |
2012 |
| Biological |
allogeneic natural killer cell line nk-92 |
1 |
2016 |
| Procedure |
allogeneic pbsct |
1 |
2008 |
| Procedure |
allogeneic pbsct/bmt |
1 |
2008 |
| Procedure |
allogeneic related stem cell transplant |
1 |
2011 |
| Procedure |
allogeneic stem cell infusion |
1 |
2012 |
| Procedure |
allogeneic stem cell transplant |
1 |
2009 |
| Other |
allogeneic stem cell transplantation with a haplo-identical family donor graft |
1 |
2019 |
| Other |
allogeneic stem cell transplantation with a matched unrelated donor graft |
1 |
2019 |
| Procedure |
allogeneic transplant |
1 |
2013 |
| Procedure |
allogeneic transplantation |
1 |
2011 |
| Drug |
allogenic nk cells infusion |
1 |
2013 |
| Drug |
allogenic stem cell transplant (asct) |
1 |
2007 |
| Procedure |
allogenic transplantation |
1 |
2007 |
| Biological |
alloreactive nk cell infusion |
1 |
2019 |
| Procedure |
alloreactive nk infusion |
1 |
2006 |
| Biological |
allostim |
1 |
2007 |
| Drug |
alrn-6924 |
1 |
2016 |
| Drug |
alrn-6924 in combination with cytarabine |
1 |
2016 |
| Biological |
alt803 |
1 |
2016 |
| Drug |
alternative anti-cancer treatment |
1 |
2012 |
| Drug |
alternative anticancer treatment |
1 |
2012 |
| Procedure |
alternative medicine procedure |
1 |
2003 |
| Drug |
alvespimycin hydrochloride |
1 |
2004 |
| Drug |
alvocidib (flavopiridol) |
1 |
2019 |
| Drug |
alvocidib (flavopiridol)/cytarabine (ara-c) |
1 |
2019 |
| Drug |
alvocidib hydrochloride |
1 |
2008 |
| Drug |
ambisome |
1 |
2006 |
| Drug |
amg 176 |
1 |
2015 |
| Drug |
amg 232 |
1 |
2013 |
| Drug |
amg 319 |
1 |
2011 |
| Drug |
amg 397 |
1 |
2018 |
| Drug |
amg 427 |
1 |
2018 |
| Drug |
amg 673 |
1 |
2017 |
| Drug |
aminolevulinic acid hydrochloride |
1 |
2003 |
| Drug |
aml induction |
1 |
2016 |
| placebo |
aml induction (placebo) |
1 |
2016 |
| Drug |
amn107 |
1 |
2005 |
| Drug |
amonafide l-malate |
1 |
2006 |
| Drug |
amp |
1 |
2010 |
| Drug |
amufostine (ethyol) |
1 |
2004 |
| Biological |
amv564 |
1 |
2017 |
| Combination Product |
amv564 in combination with pembrolizumab |
1 |
2017 |
| Drug |
anidulafungin 200 mg q48h |
1 |
2010 |
| Drug |
anidulafungin 300 mg q72h |
1 |
2010 |
| Other |
ankle range of motion |
1 |
2008 |
| Device |
anodal tdcs treatment |
1 |
2019 |
| Biological |
anti-cd123-car-transduced t cells |
1 |
2016 |
| Biological |
anti-cd19- car |
1 |
2012 |
| Biological |
anti-cd19 car-t cells injection |
1 |
2019 |
| Combination Product |
anti-cd19 car transduced t cells |
1 |
2017 |
| Biological |
anti-cd19/20-car vector-transduced t cells |
1 |
2017 |
| Biological |
anti-cd19/22-car vector-transduced t cells |
1 |
2017 |
| Biological |
anti-cd19/cd22 car-t cells |
1 |
2019 |
| Biological |
anti-cd20-car-transduced t cells |
1 |
2015 |
| Biological |
anti-cd22 immunotoxins |
1 |
2007 |
| Drug |
anti-cd45 |
1 |
2003 |
| Biological |
anti-endosialin |
1 |
2012 |
| Biological |
anti-endosialin/tem1 monoclonal antibody morab-004 |
1 |
2012 |
| Drug |
anti-lymphocyte globulin |
1 |
2015 |
| Biological |
anti-ox40 agonist monoclonal antibody pf-04518600 |
1 |
2017 |
| Drug |
anti-pr1 |
1 |
2015 |
| Drug |
anti-pr1/hla-a2 monoclonal antibody hu8f4 |
1 |
2015 |
| Drug |
anti-tac(fv)-pe38 (lmb-2) immunotoxin |
1 |
2006 |
| Drug |
anti-thymocyte globulin (atg) |
1 |
2018 |
| Drug |
anti-thymocyte globulin iv |
1 |
2008 |
| Drug |
antibodies as follows: |
1 |
2005 |
| Procedure |
antibody-drug conjugate therapy |
1 |
2005 |
| Other |
antitumor drug screening assay |
1 |
2013 |
| Drug |
antroquinonol |
1 |
2019 |
| Drug |
aop2014 |
1 |
2017 |
| Drug |
aop2014 / pegylated-proline-interferon alpha-2b |
1 |
2017 |
| Drug |
apixaban |
1 |
2015 |
| Drug |
apo866 |
1 |
2007 |
| Procedure |
application of activated donor t cells |
1 |
2007 |
| Drug |
apto-253 |
1 |
2014 |
| Drug |
apx001 with standard of care anti-fungal agent |
1 |
2017 |
| Drug |
ar-42 |
1 |
2010 |
| Drug |
ara-c (cytarabine) |
1 |
2009 |
| Drug |
ara-c (cytosine arabinoside) |
1 |
2006 |
| Drug |
ara-c, mitoxantrone, daunorubicin, thioguanin |
1 |
2011 |
| Drug |
arginine butyrate |
1 |
2000 |
| Drug |
argx-110 |
1 |
2017 |
| Device |
arm 1 |
1 |
2019 |
| Drug |
arm 1- dose escalation |
1 |
2011 |
| Drug |
arm 2- dose expansion |
1 |
2011 |
| Drug |
arm a mylotarg |
1 |
2014 |
| Drug |
arm a mylotarg/da versus cpx-351 |
1 |
2014 |
| Drug |
arm b vosaroxin |
1 |
2014 |
| Drug |
arm b vosaroxin/decitabine |
1 |
2014 |
| Drug |
arm c da v flag-ida v dac |
1 |
2014 |
| Drug |
arm d small molecule |
1 |
2014 |
| Drug |
arm d small molecule/not |
1 |
2014 |
| Drug |
arm e cpx-351 (200 v 300) |
1 |
2014 |
| Drug |
arm f da v idac |
1 |
2014 |
| Drug |
arm ii |
1 |
2007 |
| Procedure |
aromatherapy |
1 |
2015 |
| Procedure |
aromatherapy/essential oils |
1 |
2015 |
| Drug |
arq 531 |
1 |
2017 |
| Drug |
arry-520, ksp(eg5) inhibitor; intravenous |
1 |
2008 |
| Drug |
arsenic |
1 |
2012 |
| Drug |
arsenic trioxide (ato) |
1 |
2006 |
| Biological |
as01b |
1 |
2013 |
| Drug |
as1411 |
1 |
2007 |
| Drug |
ascentage pharma hqp1351 bioavailable inhibitor |
1 |
2019 |
| Drug |
asciminib add-on |
1 |
2018 |
| Drug |
aslan003 |
1 |
2018 |
| Drug |
asp |
1 |
2009 |
| Drug |
asp1235 |
1 |
2016 |
| Biological |
asp7517 |
1 |
2019 |
| Procedure |
aspirate |
1 |
2017 |
| Drug |
astarabine (bst-236) |
1 |
2015 |
| Biological |
astatine at 211 anti-cd45 monoclonal antibody bc8-b10 |
1 |
2018 |
| Drug |
astx030 (cedazuridine |
1 |
2020 |
| Drug |
astx030 (cedazuridine / azacitidine) |
1 |
2020 |
| Drug |
astx660 |
1 |
2019 |
| Drug |
astx727 / day 2 food |
1 |
2019 |
| Drug |
astx727 / day 4 food |
1 |
2019 |
| Drug |
at7519m |
1 |
2012 |
| Biological |
atg (rabbit) |
1 |
2019 |
| Drug |
atg (thymoglobulin) |
1 |
2009 |
| Drug |
atg fresenius (anti-lymphocyte-globulin) |
1 |
2008 |
| Drug |
atg thymoglobulin |
1 |
2013 |
| Biological |
atir |
1 |
2013 |
| Drug |
ato |
1 |
2014 |
| Drug |
atorvastatin calcium |
1 |
2012 |
| Drug |
atovaquone |
1 |
2018 |
| Drug |
atra/6-mp/mtx |
1 |
2009 |
| Drug |
atra/arsenic |
1 |
2012 |
| Drug |
atra/chemo |
1 |
2012 |
| Other |
attention test |
1 |
2019 |
| Drug |
atuveciclib, bay1143572 |
1 |
2015 |
| Drug |
auranofin |
1 |
2011 |
| Biological |
auto-hsct |
1 |
2018 |
| Biological |
auto1 |
1 |
2020 |
| Biological |
auto3 (cd19 |
1 |
2017 |
| Biological |
auto3 (cd19/22 car t cells |
1 |
2017 |
| Biological |
autologous |
1 |
2008 |
| Procedure |
autologous-autologous tandem hematopoietic stem cell transplantation |
1 |
2007 |
| Biological |
autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes |
1 |
2013 |
| Biological |
autologous cd123car-cd28-cd3zeta-egfrt-expressing t lymphocytes |
1 |
2014 |
| Biological |
autologous cd19-targeting car t cells |
1 |
2019 |
| Biological |
autologous cd19 car |
1 |
2012 |
| Biological |
autologous cd19 car/ egftt / t cells |
1 |
2012 |
| Biological |
autologous cd19car-cd28-cd3zeta-egfrt-expressing tn |
1 |
2014 |
| Biological |
autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes |
1 |
2014 |
| Biological |
autologous cik cell infusion |
1 |
2008 |
| Biological |
autologous dendritic cells electroporated with wt1 mrna |
1 |
2017 |
| Biological |
autologous epstein-barr virus-specific cytotoxic t lymphocytes |
1 |
2000 |
| Drug |
autologous fecal microbiota transplantation |
1 |
2016 |
| Procedure |
autologous hct |
1 |
2002 |
| Procedure |
autologous hematopoietic cell transplantation |
1 |
2010 |
| Procedure |
autologous hsct |
1 |
2018 |
| Biological |
autologous human anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4 |
1 |
2017 |
| Biological |
autologous human anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4//cd8/ t-lymphocytes |
1 |
2017 |
| Biological |
autologous humanized anti-cd22 chimeric antigen receptor t cells |
1 |
2020 |
| Biological |
autologous multi-lineage potential cells (ampc) |
1 |
2019 |
| Other |
autologous nk cells infusions |
1 |
2014 |
| Procedure |
autologous pbsct |
1 |
2005 |
| Other |
autologous peripheral blood stem cell transplantation. |
1 |
2012 |
| Biological |
autologous tumor cells |
1 |
2005 |
| Biological |
autologous wt1-tcrc4 gene-transduced cd8-positive tcm |
1 |
2016 |
| Biological |
autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes |
1 |
2016 |
| Genetic |
autologous wt1 tcr transduced t cells |
1 |
2015 |
| Biological |
autologous/syngeneic pbtls/ebv-ctls |
1 |
2008 |
| Drug |
avl-292 |
1 |
2011 |
| Drug |
avn-944 capsules for oral administration |
1 |
2006 |
| Drug |
axitinib |
1 |
2016 |
| Drug |
azacitidine (aza) |
1 |
2011 |
| Drug |
azacitidine (baml-16-001-s16) |
1 |
2016 |
| Drug |
azacitidine (baml-16-001-s2) |
1 |
2016 |
| Drug |
azacitidine (baml-16-001-s3) |
1 |
2016 |
| Drug |
azacitidine (baml-16-001-s4) |
1 |
2016 |
| Drug |
azacitidine (baml-16-001-s9) |
1 |
2016 |
| Drug |
azacitidine 75 mg |
1 |
2016 |
| Drug |
azacitidine 75 mg/m^2 |
1 |
2016 |
| Drug |
azacitidine injection |
1 |
2019 |
| Drug |
azacitidine) |
1 |
2020 |
| Drug |
azacitidine/eltrombopag |
1 |
2011 |
| Drug |
azacitidine/venetoclax |
1 |
2018 |
| Drug |
azd2811 |
1 |
2017 |
| Drug |
azd4573 |
1 |
2017 |
| Drug |
azd5991 |
1 |
2017 |
| Drug |
azd5991 / venetoclax |
1 |
2017 |
| Drug |
azd6738 |
1 |
2018 |
| Drug |
bactrim |
1 |
2005 |
| Drug |
bafetinib |
1 |
2010 |
| Drug |
bay1436032 |
1 |
2017 |
| Drug |
bay2402234 |
1 |
2017 |
| Drug |
bcl-2 inhibitor gdc-0199 |
1 |
2015 |
| Biological |
bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine |
1 |
2007 |
| Biological |
bcr-abl peptide vaccine |
1 |
1999 |
| Drug |
bcr-abl tyrosine kinase inhibitor (tki) |
1 |
2018 |
| Drug |
bcx-1777 |
1 |
2002 |
| Drug |
becatecarin |
1 |
2004 |
| Other |
bedside assessment |
1 |
2016 |
| Behavioral |
behavioral intervention |
1 |
2012 |
| Other |
behavioral, psychological |
1 |
2019 |
| Other |
behavioral, psychological/informational intervention |
1 |
2019 |
| Drug |
benadryl |
1 |
2009 |
| Drug |
benadryl/tylenol |
1 |
2009 |
| Drug |
bendamustine at a dose of 100 mg |
1 |
2011 |
| Drug |
bendamustine at a dose of 100 mg/m2 |
1 |
2011 |
| Drug |
bendamustine at a dose of 120 mg |
1 |
2011 |
| Drug |
bendamustine at a dose of 120 mg/m2 |
1 |
2011 |
| Drug |
bendamustine hydrochloride injection |
1 |
2010 |
| Drug |
bendamustine, rituximab, lenalidomide |
1 |
2011 |
| Drug |
bendamustine/lenalidomide |
1 |
2009 |
| Drug |
best available care |
1 |
2018 |
| Drug |
best available therapy |
1 |
2020 |
| Drug |
beyond according to investigator choice. |
1 |
2011 |
| Biological |
bi-1206 single agent dose escalation phase |
1 |
2016 |
| Biological |
bi-1206 single agent expansion phase |
1 |
2016 |
| Drug |
bi 2536 |
1 |
2008 |
| Drug |
bi 6727 (d1 |
1 |
2008 |
| Drug |
bi 6727 (d1/15) |
1 |
2008 |
| Drug |
bi 811283 (d 1 |
1 |
2008 |
| Drug |
bi 811283 (d 1/15) |
1 |
2008 |
| Drug |
bi 811283 (d1) |
1 |
2008 |
| Biological |
bi 836858 (baml-16-001-s2) |
1 |
2016 |
| Drug |
bicanorm |
1 |
2020 |
| Procedure |
bioelectric impedance analysis |
1 |
2013 |
| Drug |
bisantrene |
1 |
2019 |
| Radiation |
bismuth bi213 monoclonal antibody m195 |
1 |
2001 |
| Drug |
biweekly-chop with g-csf |
1 |
2005 |
| Drug |
biweekly-chop with g-csf/intrathecal prophylaxis |
1 |
2005 |
| Drug |
bkm120 |
1 |
2011 |
| Drug |
bl-nhl |
1 |
2009 |
| Drug |
bl22 |
1 |
2003 |
| Biological |
blinatumomab (mt103) |
1 |
2007 |
| Biological |
blinatumomab expanded t-cells (bet) |
1 |
2019 |
| Drug |
blinatumomab in combination with donor lymphocyte infusion |
1 |
2019 |
| Drug |
blinatumomab injection |
1 |
2018 |
| Procedure |
blood |
1 |
2019 |
| Procedure |
blood cell transplantation |
1 |
1999 |
| Other |
blood pressure |
1 |
2014 |
| Procedure |
blood test |
1 |
2007 |
| Other |
blood test, urine test, |
1 |
2007 |
| Other |
blood test, urine test,/bone density x-ray. |
1 |
2007 |
| Procedure |
blood/marrow transplant (bmt) |
1 |
2019 |
| Drug |
blr-cll |
1 |
2009 |
| Drug |
blr-nhl |
1 |
2009 |
| Drug |
bmn 673 |
1 |
2011 |
| Drug |
bms-214662 |
1 |
2000 |
| Drug |
bms-833923 |
1 |
2010 |
| Drug |
bms-906024 |
1 |
2011 |
| Drug |
bms-936564 (anti-cxcr4) |
1 |
2010 |
| Procedure |
bmt |
1 |
2008 |
| Drug |
bnz132-1-40 |
1 |
2017 |
| Other |
body composition/vital signs |
1 |
2008 |
| Other |
bone density x-ray. |
1 |
2007 |
| Other |
bone marrow aspirate |
1 |
2014 |
| Procedure |
bone marrow biopsy/aspirate |
1 |
2017 |
| Procedure |
bone marrow for correlative studies |
1 |
2013 |
| Biological |
bone marrow sample |
1 |
2015 |
| Other |
bone marrow transplant (bmt) |
1 |
2019 |
| Drug |
bortezomib 1.0mg |
1 |
2006 |
| Drug |
bortezomib 1.0mg/m^2 |
1 |
2006 |
| Drug |
bortezomib 1.3mg |
1 |
2006 |
| Drug |
bortezomib 1.3mg/m^2 |
1 |
2006 |
| Drug |
bortezomib injection |
1 |
2020 |
| Drug |
bortezomib with mitoxantrone, etoposide |
1 |
2006 |
| Drug |
bortezomib with mitoxantrone, etoposide/cytarabine |
1 |
2006 |
| Dietary Supplement |
bovine colostrum |
1 |
2013 |
| Drug |
bp1001 |
1 |
2010 |
| Drug |
bp1001 in combination with ldac |
1 |
2010 |
| Biological |
bpx-501 dose 1 |
1 |
2012 |
| Biological |
bpx-501 dose 2 |
1 |
2012 |
| Biological |
bpx-501 dose 3 |
1 |
2012 |
| Biological |
bpx-501 dose 4 |
1 |
2012 |
| Drug |
br/ibrutinib |
1 |
2019 |
| Other |
brain games stimulation |
1 |
2014 |
| Drug |
brd4 inhibitor plx51107 |
1 |
2019 |
| Drug |
brequinar |
1 |
2018 |
| Drug |
brequinar / ribavirin |
1 |
2018 |
| Other |
bsc |
1 |
2015 |
| Behavioral |
bsma |
1 |
2015 |
| Drug |
bst-236 |
1 |
2018 |
| Drug |
btct4465a (mosunetuzumab) iv |
1 |
2015 |
| Drug |
btct4465a (mosunetuzumab) sc |
1 |
2015 |
| Drug |
btx-a51 |
1 |
2020 |
| Drug |
bucy vs buflu |
1 |
2008 |
| Drug |
buparlisib |
1 |
2015 |
| Other |
buschke selective reminding test |
1 |
2019 |
| Drug |
busulfan-cyclophosphamide as conditioning regimen before allogeneic hematopoietic stem cell transplantation |
1 |
2013 |
| Procedure |
busulfan pharmacokinetics |
1 |
2005 |
| Other |
busulfan plasma level measurements |
1 |
2015 |
| Drug |
busulfan plus |
1 |
2011 |
| Drug |
busulfan x 4 |
1 |
2011 |
| Drug |
busulfan, fludarabine, cytoxan |
1 |
2008 |
| Drug |
busulfan, melphalan, fludarabine, anti-thymocyte globulin, palifermin, stem cell transplant |
1 |
2008 |
| Drug |
busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf |
1 |
2007 |
| Drug |
busulphan |
1 |
2019 |
| Drug |
bvd-523 |
1 |
2014 |
| Procedure |
c |
1 |
2009 |
| Biological |
c-myb antisense oligonucleotide g4460 |
1 |
1999 |
| Drug |
c14 azd1152 |
1 |
2009 |
| Drug |
ca-4948 |
1 |
2020 |
| Drug |
cabazitaxel |
1 |
2019 |
| Drug |
cag regimen (aclacinomycin, cytarabine, with |
1 |
2015 |
| Drug |
cag regimen (aclacinomycin, cytarabine, with/w/o g-csf) |
1 |
2015 |
| Drug |
cal-101 |
1 |
2008 |
| Dietary Supplement |
calcium |
1 |
2007 |
| Drug |
calcium carbonate (tums), vitamin d |
1 |
2005 |
| Dietary Supplement |
calcium citrate |
1 |
2011 |
| Drug |
campath-1 h (alemtuzumab) |
1 |
2002 |
| Biological |
campath] |
1 |
2004 |
| Drug |
capecitabine |
1 |
2010 |
| Drug |
capotenâ® |
1 |
2017 |
| Biological |
car-t cell immunotherapy |
1 |
2018 |
| Biological |
car-t cell therapy |
1 |
2019 |
| Biological |
car-t cells |
1 |
2019 |
| Biological |
car-t infusion |
1 |
2019 |
| Biological |
car-t19 |
1 |
2019 |
| Biological |
car-t19/car-t22 |
1 |
2019 |
| Biological |
car-t22 |
1 |
2019 |
| Biological |
car t-cell therapy |
1 |
2019 |
| Biological |
car.19 |
1 |
2017 |
| Biological |
carcik-cd19 |
1 |
2017 |
| Behavioral |
cardiorespiratory assessment |
1 |
2007 |
| Drug |
care supports |
1 |
2016 |
| Biological |
cart-19/22 |
1 |
2018 |
| Biological |
cart-38 |
1 |
2020 |
| Biological |
cart 19 |
1 |
2016 |
| Biological |
cart therapy in acute myeloid leukemia(aml) |
1 |
2018 |
| Biological |
cart123 cells; cyclophosphamide; fludarabine |
1 |
2018 |
| Biological |
cart19 cell |
1 |
2018 |
| Biological |
cart19 cell/auto-hsct |
1 |
2018 |
| Biological |
cart22-65s cells |
1 |
2018 |
| Biological |
cart22 cells transduced with a lentiviral vector to express anti-cd22 scfv tcrz:41bb |
1 |
2015 |
| Drug |
carvedilol |
1 |
2010 |
| Drug |
caspofungin |
1 |
2007 |
| Drug |
cat-8015 (moxetumomab pasudotox) |
1 |
2008 |
| Drug |
cat-8015 20 mcg |
1 |
2009 |
| Drug |
cat-8015 20 mcg/kg |
1 |
2009 |
| Drug |
cat-8015 30 mcg |
1 |
2009 |
| Drug |
cat-8015 30 mcg/kg |
1 |
2009 |
| Drug |
cat-8015 40 mcg |
1 |
2009 |
| Drug |
cat-8015 40 mcg/kg |
1 |
2009 |
| Drug |
cat-8015 50 mcg |
1 |
2009 |
| Drug |
cat-8015 50 mcg/kg |
1 |
2009 |
| Drug |
cat-8015 60 mcg |
1 |
2009 |
| Drug |
cat-8015 60 mcg/kg |
1 |
2009 |
| Drug |
cat 8015 (moxetumomab pasudotox) |
1 |
2007 |
| Device |
cathodal tdcs treatment |
1 |
2019 |
| Drug |
cb-5339 |
1 |
2020 |
| Drug |
cb-839 |
1 |
2014 |
| Drug |
cb-aza |
1 |
2014 |
| Drug |
cc-1088 |
1 |
2000 |
| Drug |
cc-122 |
1 |
2015 |
| Drug |
cc-90009 |
1 |
2016 |
| Biological |
cd10 |
1 |
2019 |
| Biological |
cd123 |
1 |
2019 |
| Drug |
cd123-car t |
1 |
2020 |
| Biological |
cd123-cd33 ccar t cells |
1 |
2019 |
| Biological |
cd123-specific gene-engineered t cells |
1 |
2017 |
| Biological |
cd123car-41bb-cd3zeta-egfrt-expressing t cells |
1 |
2017 |
| Biological |
cd19- specific car engineered autologous t-cells (sjcar19 product) |
1 |
2018 |
| Biological |
cd19-car-t cells |
1 |
2018 |
| Biological |
cd19-tricar-t |
1 |
2019 |
| Biological |
cd19-tricar-t/silk |
1 |
2019 |
| Biological |
cd19 car t-cells |
1 |
2015 |
| Combination Product |
cd19 cart |
1 |
2019 |
| Biological |
cd19 ucartcells |
1 |
2019 |
| Biological |
cd19.car t cells |
1 |
2018 |
| Biological |
cd19/ |
1 |
2019 |
| Biological |
cd19/cd22 car t-cells |
1 |
2018 |
| Genetic |
cd19car |
1 |
2009 |
| Genetic |
cd19car-28-zeta t cells |
1 |
2007 |
| Biological |
cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes |
1 |
2014 |
| Biological |
cd19car-cd28-cd3zeta-egfrt-expressing tn |
1 |
2014 |
| Biological |
cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes |
1 |
2014 |
| Genetic |
cd19car/virus specific t cells |
1 |
2009 |
| Biological |
cd19cat-41bbz car t-cells |
1 |
2016 |
| Drug |
cd22 car-t cell immunotherapy |
1 |
2019 |
| Biological |
cd22 car t-cells |
1 |
2018 |
| Biological |
cd22 specific car |
1 |
2017 |
| Biological |
cd25hi treg depleted dli |
1 |
2019 |
| Biological |
cd28 stimulated t cells |
1 |
2009 |
| Biological |
cd3-depleted |
1 |
2011 |
| Biological |
cd3-depleted/cd56/ selected natural killer cells collected from apheresis products |
1 |
2011 |
| Biological |
cd33 |
1 |
2017 |
| Biological |
cd33cart |
1 |
2019 |
| Other |
cd34/ selection |
1 |
2012 |
| Biological |
cd34/ selection with clinimacs device |
1 |
2005 |
| Other |
cd34/ selection. |
1 |
2012 |
| Biological |
cd4 |
1 |
2017 |
| Other |
cd4 dli |
1 |
2010 |
| Biological |
cd40 ligand |
1 |
2007 |
| Biological |
cd40 ligand/il-2-expressing tumor cells vaccine |
1 |
2007 |
| Biological |
cd45ra-depleted dli |
1 |
2019 |
| Biological |
cd45ra-depleted pbscs |
1 |
2019 |
| Biological |
cd45ra-depleted peripheral blood mononuclear cells |
1 |
2015 |
| Device |
cd45ra depleted peripheral stem cell addback |
1 |
2019 |
| Biological |
cd4car |
1 |
2018 |
| Biological |
cd7-specific car gene-engineered t cells |
1 |
2019 |
| Drug |
cd7 car-t cells infusion |
1 |
2019 |
| Drug |
cd8/ memory t cell selection |
1 |
2019 |
| Biological |
cd8//cd4/ donor memory t-cells-expressing ha1-specific tcr |
1 |
2017 |
| Drug |
cdiag regimen |
1 |
2019 |
| Drug |
cedazuridine |
1 |
2020 |
| Drug |
cediranib, azd2171, recentin |
1 |
2006 |
| Drug |
cefepime hydrochloride |
1 |
2011 |
| Drug |
cefepime injection |
1 |
2019 |
| Drug |
ceftazidime injection |
1 |
2019 |
| Drug |
celecoxib |
1 |
2019 |
| Drug |
cellcept |
1 |
2018 |
| Drug |
cenersen |
1 |
2003 |
| Radiation |
central nervous system (cns) prophylaxis radiation |
1 |
2005 |
| Drug |
cep-701 |
1 |
2004 |
| Drug |
cep-701 40mg |
1 |
2002 |
| Drug |
cep-701 60mg |
1 |
2002 |
| Drug |
cep-701 80mg |
1 |
2002 |
| Drug |
cephalexin |
1 |
2013 |
| Drug |
ceralasertib |
1 |
2017 |
| Drug |
cerdulatinib (prt062070) |
1 |
2013 |
| Drug |
cerubidine |
1 |
2009 |
| Drug |
cfi-400945 fumarate |
1 |
2017 |
| Drug |
chemo |
1 |
2012 |
| Drug |
chemoimmunotherapy |
1 |
2019 |
| Other |
chemosensitivity assay |
1 |
2015 |
| Drug |
chemotherapy (aracytine |
1 |
2009 |
| Drug |
chemotherapy (aracytine / daunorubicin) |
1 |
2009 |
| Drug |
chemotherapy (daunorubicine-cytarabine) |
1 |
2007 |
| Drug |
chemotherapy / blinatumomab |
1 |
2017 |
| Biological |
chemotherapy starting |
1 |
2016 |
| Procedure |
chemotherapy, intrathecal chemotherapy |
1 |
2005 |
| Drug |
chep |
1 |
2017 |
| Biological |
chimeric antigen receptor modified t cells targeting cd19 |
1 |
2015 |
| Biological |
chimeric antigen receptor t cell |
1 |
2020 |
| Biological |
chimeric antigen receptor t cells |
1 |
2017 |
| Drug |
chk1 inhibitor sch 900776 |
1 |
2013 |
| Procedure |
chlorhexidine gluconate skin cleanser |
1 |
2013 |
| Drug |
choline magnesium trisalicylate |
1 |
2014 |
| Drug |
chop-daclizumab |
1 |
2011 |
| Drug |
chop regimen |
1 |
2003 |
| Drug |
chr-2797 (tosedostat): aminopeptidase inhibitor |
1 |
2008 |
| Biological |
chronic myeloid leukemia |
1 |
2017 |
| Biological |
chronic myeloid leukemia / nk cell |
1 |
2017 |
| Drug |
ciclophosphamide |
1 |
2014 |
| Drug |
ciclopirox olamine |
1 |
2009 |
| Drug |
cik-cells |
1 |
2016 |
| Drug |
cilengitide |
1 |
2000 |
| Biological |
ciml nk |
1 |
2019 |
| Drug |
ciprofloxacin |
1 |
2016 |
| Drug |
cisplatin |
1 |
1999 |
| Drug |
cladribine s.c. injection, hcl treatment |
1 |
2014 |
| Drug |
cladribine, cyclophosphamide, cytarabine, daunorubicin, dexamethasone |
1 |
2005 |
| Drug |
cladribine, cytarabine, |
1 |
2019 |
| Drug |
cladribine, cytarabine, mitoxantrone, g-csf (clag-m) regimen |
1 |
2017 |
| Drug |
cladribine, cytarabine,/granulocyte-colony stimulating factor with fractionated gemtuzumab ozogamicin (clag-go) |
1 |
2019 |
| Drug |
clag regimen |
1 |
2009 |
| Drug |
clara |
1 |
2009 |
| Device |
clinimacs cd34 |
1 |
2014 |
| Device |
clinimacs cd34 selection system |
1 |
2014 |
| Device |
clinimacs cd34/ reagent system |
1 |
2014 |
| Device |
clinimacs cell processing system for tcrî±î² |
1 |
2019 |
| Device |
clinimacs cell processing system for tcrî±î² / t cell/cd45ra depleted peripheral stem cell addback |
1 |
2019 |
| Device |
clinimacs system |
1 |
2005 |
| Device |
clinimacs tcr alpha-beta-biotin system |
1 |
2015 |
| Biological |
cll-1, cd33 and |
1 |
2019 |
| Biological |
cll-1, cd33 and/or cd123-specific car gene-engineered t cells |
1 |
2019 |
| Biological |
cll1 |
1 |
2017 |
| Biological |
cll1-cd33 ccar t cells |
1 |
2019 |
| Drug |
clofarabine for remission induction |
1 |
2009 |
| Drug |
clofarabine in conditioning before transplantation |
1 |
2009 |
| Drug |
clofarabine incorporated into a 5-drug regimen |
1 |
2009 |
| Drug |
clofarabine vp 16 ciclophospahamide |
1 |
2011 |
| Drug |
clofarabine with busulfan |
1 |
2009 |
| Drug |
clofarabine, cyclophosphamide |
1 |
2011 |
| Drug |
clofarabine, methotrexate, mercaptopurine, dexamethasone, etoposide, dasatinib |
1 |
2007 |
| Drug |
clofarabine/busulfan x 4 |
1 |
2011 |
| Drug |
clofarabine/cytarabine |
1 |
2006 |
| Biological |
clt-008 |
1 |
2014 |
| Biological |
cm-cs1 t-cell infusion |
1 |
2014 |
| Drug |
cmc-544 (inotuzumab ozogamycin) |
1 |
2010 |
| Biological |
cmvpp65-a*0201 peptide vaccine |
1 |
2015 |
| Drug |
co-argi-peg modified human arginase i |
1 |
2016 |
| Drug |
cobimetinib |
1 |
2016 |
| Drug |
cobomarsen |
1 |
2015 |
| Other |
cognitive assessment |
1 |
2014 |
| Behavioral |
cognitive behavior therapy |
1 |
2018 |
| Biological |
collection of blood samples |
1 |
2015 |
| Other |
collection of leukemia cells |
1 |
2008 |
| Procedure |
collection of pbmcs |
1 |
2013 |
| Procedure |
collection of treatment-stratefying prognostic factors |
1 |
2005 |
| Biological |
combination of bi-1206 with rituximab |
1 |
2016 |
| Drug |
combination therapy using decitabine |
1 |
2010 |
| Drug |
combination therapy using decitabine/midostaurin |
1 |
2010 |
| Drug |
combined use of azacitidine, valproic acid, hydroxurea |
1 |
2011 |
| Drug |
combined use of azacitidine, valproic acid, hydroxurea/eventually donor leukocyte infusions. |
1 |
2011 |
| Procedure |
complementary |
1 |
2003 |
| Procedure |
complementary/alternative medicine procedure |
1 |
2003 |
| Behavioral |
compliance monitoring |
1 |
2012 |
| Other |
compliance supporting measures |
1 |
2010 |
| Drug |
compound ac220 |
1 |
2009 |
| Drug |
conditioning chemotherapy |
1 |
2007 |
| Drug |
conditioning treatment “thiotepa-treosulfan-fludarabine” |
1 |
2018 |
| Drug |
consolidation chemotherapy |
1 |
2013 |
| Drug |
conventional care |
1 |
2016 |
| Drug |
conventional care regimen |
1 |
2010 |
| Drug |
conventional chemotherapy (arac |
1 |
2009 |
| Drug |
conventional chemotherapy (arac / daunorubicin), |
1 |
2009 |
| Procedure |
conventional surgery |
1 |
2001 |
| Biological |
conventional t cells (tcon) |
1 |
2012 |
| Biological |
conventional t cells (tcon)/regulatory t cells (treg) |
1 |
2012 |
| Drug |
cop, copadm8, cyve |
1 |
2010 |
| Drug |
cop, copd m3, cym |
1 |
2010 |
| Drug |
copad |
1 |
2010 |
| Drug |
copanlisib hydrochloride |
1 |
2019 |
| Biological |
cord blood |
1 |
2011 |
| Biological |
cord blood stem cells |
1 |
2019 |
| Other |
cord blood unit |
1 |
2016 |
| Drug |
cordycepin |
1 |
1999 |
| Other |
correlative laboratory samples |
1 |
2012 |
| Drug |
corticosteroid |
1 |
2009 |
| Drug |
corticosteroids |
1 |
2011 |
| Drug |
cp-461 |
1 |
2002 |
| Drug |
cpg 7909 |
1 |
2005 |
| Drug |
cpi-613 / high dose cytarabine/mitoxantrone |
1 |
2018 |
| Radiation |
cranial radiation |
1 |
2005 |
| Drug |
crenolanib besylate (cp-868,596-26) |
1 |
2012 |
| Drug |
csl360 |
1 |
2006 |
| Biological |
csl362 |
1 |
2012 |
| Procedure |
ct guided bone marrow sampling |
1 |
2016 |
| Device |
ct/pet scans |
1 |
2013 |
| Drug |
ct053ptsa |
1 |
2017 |
| Drug |
ct53518 |
1 |
2003 |
| Biological |
cta101 |
1 |
2019 |
| Biological |
ctl019 t-cells |
1 |
2014 |
| Drug |
ctx |
1 |
2014 |
| Drug |
curcumin |
1 |
2014 |
| Drug |
cxcr4 antagonist |
1 |
2015 |
| Biological |
cyad-02 |
1 |
2019 |
| Drug |
cyc065 |
1 |
2018 |
| Drug |
cyc140 |
1 |
2018 |
| Drug |
cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic stem cell transplantation |
1 |
2013 |
| Drug |
cyclophosphamide (non-imp) |
1 |
2020 |
| Drug |
cyclophosphamide 14.5 mg |
1 |
2016 |
| Drug |
cyclophosphamide 14.5 mg/kg/day iv on days -6, -5 |
1 |
2016 |
| Drug |
cyclophosphamide 50mg/kg/day iv on days -2,-1 |
1 |
2016 |
| Drug |
cyclophosphamide 50mg/kg/day iv on days -5,-4 |
1 |
2016 |
| Drug |
cyclophosphamide based chemotherapy regimens |
1 |
2013 |
| Drug |
cyclophosphamide for remission induction |
1 |
2009 |
| Drug |
cyclophosphamide) |
1 |
2014 |
| Drug |
cyclophosphamide, fludarabine, clofarabine, etoposide, interleukin-2 |
1 |
2005 |
| Drug |
cyclosporin-a |
1 |
2007 |
| Drug |
cyclosporine a (csa) |
1 |
2007 |
| Drug |
cyclosporine ophthalmic emulsion |
1 |
2008 |
| Drug |
cyclosporins |
1 |
2009 |
| Drug |
cyproheptadine hydrochloride |
1 |
2003 |
| Drug |
cytarabine (baml-16-001-s1) |
1 |
2016 |
| Drug |
cytarabine (baml-16-001-s6) |
1 |
2016 |
| Drug |
cytarabine arabinoside |
1 |
2010 |
| Drug |
cytarabine dosage |
1 |
2005 |
| Drug |
cytarabine induction |
1 |
2019 |
| Drug |
cytarabine regimen |
1 |
2019 |
| Drug |
cytarabine vs. cytarabine |
1 |
2005 |
| Drug |
cytarabine vs. cytarabine/amsacrine/mitoxantrone |
1 |
2005 |
| Drug |
cytarabine, all-trans retinoic acid, valproic acid |
1 |
2009 |
| Drug |
cytarabine. |
1 |
2002 |
| Drug |
cytarabine/mitoxantrone |
1 |
2012 |
| Drug |
cytarabine/supportive care |
1 |
2005 |
| Biological |
cytokine-induced killer cells |
1 |
2013 |
| Biological |
cytokine-treated veto cells |
1 |
2018 |
| Other |
cytokine assessment |
1 |
2010 |
| Other |
cytology specimen collection procedure |
1 |
2015 |
| Biological |
cytomegalovirus (cmv)-specific cytotoxic t cells (ctls) |
1 |
2014 |
| Drug |
cytosar |
1 |
2009 |
| Drug |
cytosin-arabinosid |
1 |
2005 |
| Drug |
cytosine arabinoside (ara-c) |
1 |
2005 |
| Procedure |
d-clag |
1 |
2020 |
| Drug |
da versus cpx-351 |
1 |
2014 |
| Drug |
dacogen |
1 |
2017 |
| Drug |
dacogen (decitabine) only |
1 |
2005 |
| Biological |
dactinomycin |
1 |
1999 |
| Biological |
darbopoetin |
1 |
2006 |
| Drug |
dasatinib (sprycel) |
1 |
2009 |
| Drug |
dasatinib (sprycelâ®) |
1 |
2016 |
| Drug |
dasatinib / pegifn |
1 |
2012 |
| Drug |
dasatinib, mitoxantrone, cytarabine |
1 |
2009 |
| Drug |
daunorubicin (baml-16-001-s1) |
1 |
2016 |
| Drug |
daunorubicin (baml-16-001-s6) |
1 |
2016 |
| Drug |
daunorubicin (dnr) |
1 |
2016 |
| Drug |
daunorubicin / cytarabine |
1 |
2017 |
| Drug |
daunorubicin liposomal injection [daunoxome] |
1 |
2018 |
| Drug |
daunorubicin) |
1 |
2009 |
| Drug |
daunorubicin), |
1 |
2009 |
| Drug |
daunorubicin, adriamycin |
1 |
2005 |
| Drug |
daunorubicin, cytarabine |
1 |
2017 |
| Drug |
daunorubicin, vincristine, prednisone, methotrexate, peg-asparaginase, 6-mercaptopurine, cytoxan, cytosine arabinoside, vm-26 |
1 |
2005 |
| Drug |
daunorubicin, vincristine, prednisone, methotrexate, peg-asparaginase, 6-mercaptopurine, cytoxan, cytosine arabinoside, vm-26/6-thioguanine |
1 |
2005 |
| Drug |
daunorubicine |
1 |
2018 |
| Drug |
daunoxome |
1 |
2010 |
| Drug |
day |
1 |
2011 |
| Drug |
day 2 food |
1 |
2019 |
| Drug |
day 4 food |
1 |
2019 |
| Drug |
day iv on days -2,-1 |
1 |
2016 |
| Drug |
day iv on days -5,-4 |
1 |
2016 |
| Drug |
day iv on days -6, -5 |
1 |
2016 |
| Drug |
day) |
1 |
2007 |
| Drug |
day; |
1 |
2007 |
| Biological |
dc vaccination for postremission therapy in aml |
1 |
2012 |
| Drug |
dcc-2036 |
1 |
2009 |
| Drug |
dcdt2980s |
1 |
2010 |
| Drug |
dcll9718s |
1 |
2017 |
| Drug |
decadron |
1 |
2009 |
| Drug |
decitabine (baml-16-001-s5) |
1 |
2016 |
| Drug |
decitabine (baml-16-001-s8) |
1 |
2016 |
| Drug |
decitabine (dac) |
1 |
1999 |
| Drug |
decitabine (part 1 - completed) |
1 |
2010 |
| Drug |
decitabine 15 mg |
1 |
2009 |
| Drug |
decitabine 15 mg/m2 i.v. |
1 |
2009 |
| Drug |
decitabine 20 mg |
1 |
2015 |
| Drug |
decitabine 20 mg/m^2 |
1 |
2015 |
| Drug |
decitabine, homoharringtonine, aclarubicin, cytarabine |
1 |
2019 |
| Drug |
decitabine, homoharringtonine, aclarubicin, cytarabine/g-csf |
1 |
2019 |
| Drug |
decitabine/cytarabine |
1 |
2013 |
| Drug |
decitabine/haag regimen |
1 |
2019 |
| Drug |
decitabine/modified bucy |
1 |
2017 |
| Drug |
deferasirox |
1 |
2011 |
| Biological |
deglycosylated ricin a chain-conjugated anti-cd19 |
1 |
2007 |
| Biological |
deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins |
1 |
2007 |
| Other |
demographic variables |
1 |
2008 |
| Biological |
denileukin diftitox |
1 |
2004 |
| Drug |
deoxycoformycin |
1 |
1999 |
| Drug |
deoxycytidine |
1 |
2000 |
| Procedure |
depleted haploidentical hsct |
1 |
2015 |
| Drug |
dexametasone |
1 |
2014 |
| Drug |
dexamethasona, idarubicine, ara-c, methotrexate |
1 |
2011 |
| Drug |
dexamethasone acetate |
1 |
2008 |
| Drug |
dexamethasone continuous |
1 |
2017 |
| Drug |
dexamethasone intermittent |
1 |
2017 |
| Drug |
dexamethasone/prednisolone |
1 |
2005 |
| Drug |
dexamethosone |
1 |
2004 |
| Drug |
dextromethorphan hydrobromide |
1 |
1999 |
| Drug |
dhap |
1 |
2012 |
| Procedure |
dhap rescue |
1 |
2009 |
| Procedure |
dhap rescue/autologous stem cell transplantation |
1 |
2009 |
| Procedure |
dhap rescue/f/c |
1 |
2009 |
| Other |
diet |
1 |
2017 |
| Procedure |
diffusion weighted imaging |
1 |
2015 |
| Biological |
diphtheria toxoid |
1 |
2015 |
| Biological |
diphtheria toxoid/tetanus toxoid/acellular pertussis vaccine adsorbed |
1 |
2015 |
| Other |
dli of the 20 fraction of the ucbt |
1 |
2014 |
| Genetic |
dna analysis |
1 |
2012 |
| Drug |
dnr |
1 |
2014 |
| Biological |
dnt cells |
1 |
2017 |
| Dietary Supplement |
docosahexaenoic acid (dha) |
1 |
2010 |
| Biological |
donor il-15 stimulated nk cells infusion |
1 |
2018 |
| Biological |
donor leukocyte infusion (dli) |
1 |
2011 |
| Other |
donor leukocytes |
1 |
2017 |
| Biological |
donor lymphocyte infusions |
1 |
2015 |
| Biological |
donor memory t-cells-expressing ha1-specific tcr |
1 |
2017 |
| Other |
donor search prognosis score |
1 |
2019 |
| Biological |
dose level 2- fixed dose |
1 |
2004 |
| Biological |
dose level 3 |
1 |
2003 |
| Biological |
double umbilical cord blood transplant |
1 |
2012 |
| Biological |
double umbilical cord blood unit transplant |
1 |
2006 |
| Dietary Supplement |
doxercalciferol |
1 |
2003 |
| Drug |
doxorubicin hydrochloride (hcl) |
1 |
2013 |
| Drug |
doxorubicin, l-asparaginase, peg-l-asparaginase, erwinia asparaginase |
1 |
2005 |
| Drug |
doxorubicine |
1 |
2007 |
| Drug |
doxorubicine pegylated |
1 |
2007 |
| Other |
drug withdrawn |
1 |
2019 |
| Combination Product |
drugs |
1 |
2017 |
| Combination Product |
drugs/anti-cd19 car transduced t cells |
1 |
2017 |
| Drug |
ds-3201b |
1 |
2017 |
| Drug |
dt388il3 |
1 |
2006 |
| Biological |
dtgm fusion protein |
1 |
1999 |
| Drug |
dtrm-505 |
1 |
2016 |
| Drug |
dtrmwxhs-12 |
1 |
2016 |
| Drug |
dual specificity cd19 |
1 |
2019 |
| Drug |
dual specificity cd19/cd22 car-t cell immunotherapy |
1 |
2019 |
| Drug |
during venetoclax |
1 |
2019 |
| Radiation |
dynamic contrast-enhanced computed tomography |
1 |
2014 |
| Behavioral |
dynamic muscular endurance |
1 |
2007 |
| Drug |
e-coli l-asparaginase |
1 |
2017 |
| Drug |
e. coli asparaginase |
1 |
2005 |
| Drug |
e. coli asparaginase, peg-l-asparaginase |
1 |
2005 |
| Drug |
e. coli l-asparaginase |
1 |
2005 |
| Drug |
e.coli l-asparaginase |
1 |
2013 |
| Drug |
e7070 |
1 |
2012 |
| Drug |
eagd t-cell infusion (expansion) |
1 |
2018 |
| Drug |
eagd t-cell infusion (phase i) |
1 |
2018 |
| Procedure |
early allogeneic pbsct within induction therapy |
1 |
2005 |
| Behavioral |
ease |
1 |
2015 |
| Biological |
ebv-ctls |
1 |
2008 |
| Biological |
eculizumab |
1 |
2005 |
| Drug |
edetate calcium disodium |
1 |
2018 |
| Drug |
edicotinib |
1 |
2018 |
| Behavioral |
education information system |
1 |
2019 |
| Other |
education intervention |
1 |
2015 |
| Biological |
egftt |
1 |
2012 |
| Drug |
elacytarabine/idarubicin |
1 |
2009 |
| Other |
electronic decision aid tool |
1 |
2018 |
| Drug |
enalapril |
1 |
2010 |
| Drug |
enalapril/carvedilol |
1 |
2010 |
| Drug |
endotoxin |
1 |
2009 |
| Drug |
endoxan |
1 |
2019 |
| Drug |
entinostat days 10,17 |
1 |
2011 |
| Drug |
entinostat days 3, 10 |
1 |
2011 |
| Drug |
entospletinib (baml-16-001-s4) |
1 |
2016 |
| Drug |
entospletinib (baml-16-001-s5) |
1 |
2016 |
| Drug |
entospletinib (baml-16-001-s6) |
1 |
2016 |
| Drug |
enzalutamide |
1 |
2019 |
| Drug |
enzastaurin |
1 |
2007 |
| Drug |
epirubicin |
1 |
2017 |
| Drug |
epirubicin hydrochloride |
1 |
2003 |
| Drug |
epoch-f |
1 |
2007 |
| Drug |
erlotinib hydrochloride |
1 |
2012 |
| Drug |
erwinaseâ® |
1 |
2017 |
| Drug |
erythromycin |
1 |
2015 |
| Drug |
erythropoetin |
1 |
2010 |
| Dietary Supplement |
eskimo-3 pure fish oil |
1 |
2019 |
| Procedure |
essential oils |
1 |
2015 |
| Drug |
estramustine phosphate sodium |
1 |
1999 |
| Biological |
et019003-t cells |
1 |
2019 |
| Biological |
et190l1-artemisâ„¢ t cells - iv high dose |
1 |
2019 |
| Biological |
et190l1-artemisâ„¢ t cells -iv low dose |
1 |
2019 |
| Biological |
et190l1-artemisâ„¢ t cells -iv middle dose |
1 |
2019 |
| Drug |
etoposid |
1 |
2005 |
| Drug |
etoposide for remission induction |
1 |
2009 |
| Drug |
etoposide, cytarabine, gemtuzumab, l-asparaginase, mercaptopurine, methotrexate, mitoxantrone, prednisone, vincristine |
1 |
2005 |
| Drug |
etoposide, cytarabine, vincristine, dexamethasone |
1 |
2005 |
| Drug |
etoposide, thioguanine, cyclophosphamide, busulfan, melphalan |
1 |
2005 |
| Drug |
eventually donor leukocyte infusions. |
1 |
2011 |
| Drug |
everolimus (rad001) |
1 |
2009 |
| Biological |
ex-vivo expanded cord blood progenitor cell infusion |
1 |
2009 |
| Biological |
ex-vivo expanded î³î´ t lymphocytes |
1 |
2019 |
| Other |
ex-vivo umbilical cord blood expansion |
1 |
2006 |
| Biological |
ex vivo-activated autologous lymph node lymphocytes |
1 |
2015 |
| Drug |
exatecan mesylate |
1 |
1999 |
| Other |
exercise based multimodal intervention |
1 |
2011 |
| Behavioral |
exercise program |
1 |
2007 |
| Other |
exercise therapy |
1 |
2018 |
| Behavioral |
exergaming program |
1 |
2014 |
| Procedure |
expanded allogeneic cord blood (cb) |
1 |
2003 |
| Procedure |
expanded autologous t cells |
1 |
2003 |
| Biological |
expanded haploidentical natural killer cells |
1 |
2020 |
| Biological |
expanded natural killer cells (nkaes) |
1 |
2014 |
| Procedure |
expansion of umbilical cord stem cells |
1 |
2004 |
| Drug |
experimental (fludarabine) |
1 |
2009 |
| Drug |
extracorporeal photopheresis |
1 |
2010 |
| Procedure |
f |
1 |
2009 |
| Drug |
fa |
1 |
2011 |
| Drug |
fa/tbi/cy/vp-16 |
1 |
2011 |
| Drug |
farnesyl protein transferase inhibitor |
1 |
2002 |
| Other |
fasting blood draw, measurement of height, weight |
1 |
2014 |
| Other |
fasting blood draw, measurement of height, weight/waist circumference,/blood pressure |
1 |
2014 |
| Biological |
fate-nk100 |
1 |
2017 |
| Other |
fatigue inventory |
1 |
2010 |
| Drug |
fc infusion |
1 |
2009 |
| Drug |
fccam |
1 |
2005 |
| Drug |
fcr/ibrutinib |
1 |
2019 |
| Procedure |
fdg-pet |
1 |
2016 |
| Procedure |
fdg-pet/ct guided bone marrow sampling |
1 |
2016 |
| Dietary Supplement |
ferrous sulfate |
1 |
2008 |
| Drug |
ff-10101-01 |
1 |
2017 |
| Drug |
filanesib |
1 |
2011 |
| Drug |
filgastrim |
1 |
2014 |
| Biological |
filgrastim (g-csf) |
1 |
1999 |
| Procedure |
first allogeneic bone marrow transplant (bmt) |
1 |
2011 |
| Behavioral |
fit4life |
1 |
2010 |
| Drug |
flag |
1 |
2007 |
| Drug |
flag-ida (granulocyte-colony stimulating factor (g-csf), fludarabine, cytarabine, idarubicin) |
1 |
2015 |
| Drug |
flag (fludarabine, cytarabine |
1 |
2012 |
| Drug |
flag (fludarabine, cytarabine/g-csf) |
1 |
2012 |
| Drug |
flag (granulocyte colony-stimulating factor (g-csf), fludarabine, cytarabine) |
1 |
2017 |
| Drug |
flaimy - fluda, ida, ara-c, mylotarg |
1 |
2009 |
| Other |
flexibility |
1 |
2008 |
| Biological |
flotetuzumab |
1 |
2019 |
| Other |
flt pet |
1 |
2014 |
| Other |
flt pet/ct |
1 |
2014 |
| Drug |
flu-mel |
1 |
2008 |
| Biological |
flucam [fludara |
1 |
2004 |
| Biological |
flucam [fludara / campath] |
1 |
2004 |
| Drug |
fludara |
1 |
2019 |
| Drug |
fludarabine-cladribine-busulfan conditioning regimen |
1 |
2017 |
| Drug |
fludarabine (flu) |
1 |
2018 |
| Drug |
fludarabine (non-imp) |
1 |
2020 |
| Drug |
fludarabine from -5 to -3 |
1 |
2019 |
| Drug |
fludarabine mono |
1 |
2006 |
| Drug |
fludarabine phosphate (fludara) |
1 |
2005 |
| Drug |
fludarabine(flu) |
1 |
2018 |
| Other |
fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft |
1 |
2008 |
| Drug |
fludarabine, cytarabine, filgrastim |
1 |
2018 |
| Drug |
fludarabine, cytarabine, liposomal daunorubicin (daunoxome) |
1 |
2005 |
| Drug |
fludarabine, methotrexate, mercaptopurine |
1 |
2005 |
| Drug |
fludarabine, mitoxantrone, cyclophosphamide |
1 |
2010 |
| Drug |
fludarabine, mitoxantrone, cyclophosphamide/alemtuzumab |
1 |
2010 |
| Drug |
fludarabine/ melphalan |
1 |
2011 |
| Drug |
fludarabine/busulfan |
1 |
2011 |
| Drug |
fludarabine/busulfan / low dose total body irradiation (ld tbi) |
1 |
2011 |
| Drug |
fludarabine/busulfan plus/minus total body irradiation (low dose) |
1 |
2011 |
| Drug |
fludarabine/cyclophosphamide |
1 |
2006 |
| Biological |
fludarabine/darbopoetin |
1 |
2006 |
| Radiation |
fludeoxyglucose f-18 |
1 |
2015 |
| Drug |
flumatinib |
1 |
2020 |
| Other |
fluorothymidine f-18 |
1 |
2015 |
| Biological |
flysyn |
1 |
2016 |
| Drug |
folinic acid |
1 |
2019 |
| Other |
follow-up care |
1 |
2013 |
| Other |
food safety guidelines |
1 |
2008 |
| Drug |
forodesine hcl |
1 |
2008 |
| Dietary Supplement |
fortini mf unflavoured (1.5kcal |
1 |
2012 |
| Radiation |
fractionated total body irradiation |
1 |
2016 |
| Radiation |
fractionated total body irradiation (ftbi) |
1 |
2000 |
| Drug |
fragmin |
1 |
2000 |
| Drug |
fresh frozen plasma |
1 |
2012 |
| Drug |
ft-1101 |
1 |
2015 |
| Drug |
ft-2102 (olutasidenib) |
1 |
2016 |
| Drug |
ft596 |
1 |
2020 |
| Drug |
fts |
1 |
2009 |
| Other |
functional assessment of cancer therapy-bone marrow transplant (fact-bmt) |
1 |
2018 |
| Drug |
g-csf (filgrastim) |
1 |
2009 |
| Drug |
g-csf) |
1 |
2012 |
| Drug |
g-scf |
1 |
2018 |
| Drug |
gabapentin |
1 |
2012 |
| Drug |
gadolinium |
1 |
2015 |
| Biological |
galinpepimut-s |
1 |
2020 |
| Drug |
gamma-secretase |
1 |
2010 |
| Drug |
gamma-secretase/notch signalling pathway inhibitor ro4929097 |
1 |
2010 |
| Drug |
ganetespib |
1 |
2010 |
| Drug |
gcs-100 |
1 |
2007 |
| Drug |
gdc-0853 |
1 |
2013 |
| Drug |
gefitinib |
1 |
2005 |
| Drug |
gem333 |
1 |
2018 |
| Drug |
gemcitabine/oxaliplatin |
1 |
2012 |
| Drug |
gemtuzumab |
1 |
2009 |
| Drug |
gemtuzumab ozogamicin (mylotarg) |
1 |
2009 |
| Drug |
gemtuzumab ozogamycin |
1 |
2009 |
| Biological |
gene-modified t cells targeted |
1 |
2010 |
| Genetic |
genetic variation analysis |
1 |
2015 |
| Biological |
genetically engineered lymphocyte therapy |
1 |
2008 |
| Drug |
gilteritinib (baml-16-001-s8) |
1 |
2016 |
| Drug |
glasdegib maleate |
1 |
2017 |
| Drug |
gleevec (imatinib mesylate) |
1 |
2002 |
| Drug |
glivecâ® |
1 |
2007 |
| Drug |
glivecâ®/gleevecâ® |
1 |
2007 |
| Drug |
globulina antilinfocitaria |
1 |
2006 |
| Drug |
glucarpidase |
1 |
2011 |
| Drug |
glucocorticoid |
1 |
2012 |
| Drug |
glutaminase inhibitor cb-839 |
1 |
2017 |
| Drug |
glutamine |
1 |
2006 |
| Drug |
glycosylated g-csf |
1 |
2019 |
| Biological |
gm-csf secreting leukemia vaccine |
1 |
2007 |
| Biological |
gm-csf/g-csf |
1 |
2016 |
| Biological |
gm-k562 |
1 |
2008 |
| Biological |
gm-k562 vaccine |
1 |
2007 |
| Biological |
gm-k562/leukemia cell vaccine |
1 |
2008 |
| Drug |
gmi-1271 |
1 |
2014 |
| Drug |
go-203-2c |
1 |
2014 |
| Drug |
go-203-2c / decitabine |
1 |
2014 |
| Behavioral |
go test (tgug). |
1 |
2007 |
| Drug |
grafalon |
1 |
2013 |
| Device |
graft manipulation (cd34 |
1 |
2013 |
| Device |
graft manipulation (cd34/ selection) |
1 |
2013 |
| Drug |
granisetron hydrochloride |
1 |
2006 |
| Drug |
granulocyte-colony stimulating factor |
1 |
2016 |
| Drug |
granulocyte-colony stimulating factor (g-csf) |
1 |
2017 |
| Drug |
granulocyte-colony stimulating factor with fractionated gemtuzumab ozogamicin (clag-go) |
1 |
2019 |
| Biological |
grnvac1 |
1 |
2007 |
| Other |
grooved peg board test |
1 |
2019 |
| Other |
gross motor function |
1 |
2008 |
| Drug |
gs-4059 |
1 |
2012 |
| Biological |
gsk biologicals’ recombinant wt1 antigen-specific cancer immunotherapeutic (asci) |
1 |
2008 |
| Biological |
gsk biologicals’ recombinant wt1 antigen-specific cancer immunotherapeutic (asci) gsk2130579a |
1 |
2009 |
| Drug |
gsk1120212 |
1 |
2009 |
| Drug |
gsk3326595 |
1 |
2018 |
| Drug |
gtb-3550 trikeâ„¢ phase i |
1 |
2017 |
| Drug |
gtb-3550 trikeâ„¢ phase ii |
1 |
2017 |
| Biological |
gvax |
1 |
2013 |
| Biological |
gvax leukemia vaccine (therapeutic cellular vaccine, gm-csf producing) |
1 |
2005 |
| Drug |
gx15-070ms |
1 |
2008 |
| Drug |
h3b-8800 |
1 |
2016 |
| Drug |
haag regimen |
1 |
2019 |
| Other |
hand grip strength |
1 |
2008 |
| Behavioral |
handgrip evaluation |
1 |
2007 |
| Biological |
haplo-cord stem cell transplantation |
1 |
2017 |
| Biological |
haplo-identical cells (donor) |
1 |
2015 |
| Procedure |
haplo-identical hsct |
1 |
2013 |
| Biological |
haplo bmt |
1 |
2019 |
| Biological |
haplo bmt with nk cells |
1 |
2019 |
| Procedure |
haploidentical bone marrow |
1 |
2012 |
| Biological |
haploidentical bone marrow transplant |
1 |
2012 |
| Biological |
haploidentical bone marrow transplantation |
1 |
2009 |
| Procedure |
haploidentical bone marrow/kidney |
1 |
2012 |
| Procedure |
haploidentical donor derived natural killer cell infusion |
1 |
2008 |
| Drug |
haploidentical donors |
1 |
2012 |
| Procedure |
haploidentical hematopoietic stem cell transplantation |
1 |
2007 |
| Procedure |
haploidentical hematopoietic stem cell transplantation (hsct) |
1 |
2015 |
| Procedure |
haploidentical transplantation of t-cell depleted graft |
1 |
2009 |
| Procedure |
hct |
1 |
2016 |
| Drug |
hdac |
1 |
2009 |
| Drug |
hdac inhibitor ar-42 |
1 |
2013 |
| Drug |
hdm201 |
1 |
2019 |
| Drug |
hdmp |
1 |
2010 |
| Behavioral |
health counseling |
1 |
2012 |
| Behavioral |
health counseling/exercise |
1 |
2012 |
| Biological |
heat shock protein 70 hsp70 |
1 |
2001 |
| Other |
heavy water (2h2o) |
1 |
2012 |
| Procedure |
hematopoietic cell transplant |
1 |
2015 |
| Procedure |
hematopoietic cell transplant (hct) |
1 |
2014 |
| Device |
hematopoietic stem cell transplantation (hsct) |
1 |
2011 |
| Biological |
hematopoietic umbilical cord blood stem cell transplantation |
1 |
2009 |
| Drug |
hidac (high dose cytarabine) |
1 |
2012 |
| Drug |
hidrocortisone |
1 |
2014 |
| Drug |
high-dose anthracycline |
1 |
2007 |
| Drug |
high-dose cytarabine |
1 |
2004 |
| Drug |
high-dose ia regimen |
1 |
2014 |
| Drug |
high-dose methotrexate |
1 |
2013 |
| Drug |
high-dose trivalent inactivated influenza vaccine |
1 |
2010 |
| Drug |
high dose cytarabine for consolidation |
1 |
2014 |
| Drug |
high dose cytarabine/mitoxantrone |
1 |
2018 |
| Drug |
high dose il-2 |
1 |
2019 |
| Biological |
high dose irradiation conditioning |
1 |
2019 |
| Biological |
high dose irradiation conditioning / treg/tcon |
1 |
2019 |
| Drug |
high dose methotrexate |
1 |
2015 |
| Drug |
high dose methylprednisolone (hdmp) |
1 |
2011 |
| Drug |
high dose mtx |
1 |
2009 |
| Other |
high performance liquid chromatography |
1 |
2007 |
| Dietary Supplement |
high phenolic evoo intake |
1 |
2019 |
| Device |
high throughput screening |
1 |
2017 |
| Drug |
hign dose daunorubicin |
1 |
2018 |
| Drug |
histamine dihydrochloride/il-2 |
1 |
2011 |
| Drug |
hla-a2 monoclonal antibody hu8f4 |
1 |
2015 |
| Biological |
hla-matched related donor bone marrow |
1 |
2008 |
| Other |
hla-mismatched micro-transplantation after induction chemotherapy |
1 |
2018 |
| Genetic |
hla matched stem cell |
1 |
2015 |
| Genetic |
hla mismatched stem cell |
1 |
2015 |
| Drug |
hm43239 |
1 |
2019 |
| Combination Product |
hma/dli |
1 |
2018 |
| Drug |
hmpl-306 |
1 |
2020 |
| Behavioral |
home-based exercise program |
1 |
2008 |
| Procedure |
hpc(a) stem cell allograft |
1 |
2018 |
| Biological |
hpc,a infusion |
1 |
2016 |
| Procedure |
hsct from hrd |
1 |
2015 |
| Procedure |
hsct from msd |
1 |
2015 |
| Procedure |
hsct from mud |
1 |
2015 |
| Biological |
hsct with non-tbi regimen |
1 |
2017 |
| Biological |
hsct with tbi regimen |
1 |
2017 |
| Genetic |
hsv-tk |
1 |
2009 |
| Biological |
hu-mik-beta-1 |
1 |
2004 |
| Drug |
hu5f9-g4 |
1 |
2019 |
| Biological |
hucart19 cells |
1 |
2018 |
| Drug |
hum-195 |
1 |
2002 |
| Drug |
hum-195/rgel |
1 |
2002 |
| Other |
human activity profile |
1 |
2018 |
| Drug |
human cd19 targeted t cells injection |
1 |
2019 |
| Drug |
human growth hormone |
1 |
2006 |
| Drug |
human placental derived stem cell |
1 |
2012 |
| Biological |
humanized cd19 car-t cells |
1 |
2017 |
| Biological |
humanized cd19 car-t cells with crs suppression technology |
1 |
2017 |
| Combination Product |
hva regimens as salvage treatment |
1 |
2020 |
| Drug |
hyaluronidase human |
1 |
2018 |
| Drug |
hydroxyurea/interferon-based therapy |
1 |
2019 |
| Drug |
hyper-cvad |
1 |
2010 |
| Radiation |
hyperfractionated tbi |
1 |
2019 |
| Radiation |
hyperfractionated total body irradiation |
1 |
2018 |
| Drug |
amphotericin b |
1 |
2012 |
| Biological |
î² |
1 |
2019 |
| Drug |
î³î´t cell infusion agent |
1 |
2020 |
| Drug |
iac regimen |
1 |
2014 |
| Drug |
ibrutinib (as subsequent therapy) |
1 |
2018 |
| Drug |
ibrutinib (i |
1 |
2019 |
| Drug |
ibrutinib / ofatumumab |
1 |
2015 |
| Drug |
ibrutinib / venetoclax 15 cycles |
1 |
2017 |
| Drug |
ibrutinib 140 mg oral capsule [imbruvica] |
1 |
2017 |
| Drug |
ibrutinib 420 mg |
1 |
2017 |
| Drug |
ibrutinib 560 mg |
1 |
2017 |
| Drug |
ibrutinib until progression |
1 |
2017 |
| Drug |
ibrutinib until progression/relapse |
1 |
2017 |
| Drug |
ibrutinib/thalidomide |
1 |
2019 |
| Biological |
ic9 |
1 |
2017 |
| Biological |
ic9-car19 cells |
1 |
2017 |
| Biological |
ic9/car.19/il15-transduced cb-nk cells |
1 |
2017 |
| Biological |
icar19 car-t cells |
1 |
2017 |
| Biological |
icaspase9-transduced t cells |
1 |
2011 |
| Drug |
idarubicin hydrochloride |
1 |
2014 |
| Drug |
idarubicin, etoposide, cytarbine, teniposide |
1 |
2005 |
| Drug |
idarubicin/cytarabine induction |
1 |
2019 |
| Drug |
idarubicina |
1 |
2006 |
| Drug |
idarubicine/cytarabine regimen |
1 |
2019 |
| Drug |
idarubicin(ida) |
1 |
2016 |
| Drug |
idarubincin |
1 |
2004 |
| Drug |
idarubincin/amufostine (ethyol) |
1 |
2004 |
| Drug |
idec-152 |
1 |
2002 |
| Drug |
idec-c2b8 |
1 |
2014 |
| Drug |
ign523 |
1 |
2014 |
| Biological |
il-12 |
1 |
2015 |
| Biological |
il-15/alemtuzumab |
1 |
2016 |
| Biological |
il-2-expressing tumor cells vaccine |
1 |
2007 |
| Drug |
il-4 |
1 |
2009 |
| Biological |
il15-transduced cb-nk cells |
1 |
2017 |
| Drug |
im jzp-458 |
1 |
2019 |
| Drug |
imatinib (gleevec) |
1 |
2010 |
| Drug |
imatinib (sti571) |
1 |
2007 |
| Drug |
imatinib 400 mg |
1 |
2005 |
| Drug |
imatinib 400 mg / peg-interferon |
1 |
2005 |
| Other |
imatinib discontinuation |
1 |
2016 |
| Behavioral |
imatinib ending |
1 |
2007 |
| Drug |
imatinib mesilate |
1 |
2006 |
| Drug |
imatinib mesilate (glivec) |
1 |
2007 |
| Drug |
imatinib mesylate 100 mg (glivec) |
1 |
2009 |
| Drug |
imatinib mesylate 400 mg / cytarabine |
1 |
2005 |
| Drug |
imatinib mesylate 600 mg |
1 |
2005 |
| Drug |
imatinib mesylate tablets, 400 mg |
1 |
2014 |
| Drug |
imatinib stop |
1 |
2011 |
| Drug |
imatinib, dasatinib |
1 |
2019 |
| Drug |
imatinib, dasatinib/nilotinib |
1 |
2019 |
| Drug |
imatinib/acetaminophen |
1 |
2007 |
| Drug |
imatinib/nilotinib |
1 |
2012 |
| Drug |
imatinib/pegylated interferon |
1 |
2010 |
| Drug |
imgn529 |
1 |
2012 |
| Drug |
imgn779 |
1 |
2016 |
| Biological |
imiquimod |
1 |
2018 |
| Procedure |
immunoablative hematopoietic pbsc transplant |
1 |
2005 |
| Other |
immunoenzyme technique |
1 |
2006 |
| Biological |
immunotherapy |
1 |
2008 |
| Procedure |
immunotoxin therapy |
1 |
2005 |
| Procedure |
in vitro-treated peripheral blood stem cell transplantation (pbsct) |
1 |
2000 |
| Device |
in vitro kinase inhibitor assay |
1 |
2016 |
| Drug |
in vitro sensitivity-directed chemotherapy |
1 |
2015 |
| Procedure |
in vitro treated peripheral blood stem cell transplantation |
1 |
2006 |
| Drug |
ina03 administration |
1 |
2019 |
| Drug |
incb018424 |
1 |
2008 |
| Biological |
incomplete freund’s adjuvant |
1 |
2006 |
| Radiation |
indium in 111 ibritumomab tiuxetan |
1 |
2007 |
| Radiation |
indium in 111 ll2 igg |
1 |
1999 |
| Radiation |
indium in 111 monoclonal antibody mn-14 |
1 |
1999 |
| Behavioral |
individual diet |
1 |
2014 |
| Behavioral |
individual diet/physical activity counselor/website through healthways at hopkins |
1 |
2014 |
| Biological |
individual peptide vaccination with adjuvant gm-csf |
1 |
2018 |
| Biological |
individual peptide vaccination with adjuvant gm-csf/imiquimod |
1 |
2018 |
| Behavioral |
individualized yoga intervention group |
1 |
2014 |
| Drug |
indoximod freebase |
1 |
2016 |
| Drug |
indoximod hcl f1 |
1 |
2016 |
| Drug |
indoximod hcl f2 |
1 |
2016 |
| Drug |
induction chemotherapy |
1 |
2013 |
| Drug |
induction chemotherapy (fludarabine, cytarabine, idarubicin) |
1 |
2010 |
| Procedure |
infusion of activated |
1 |
2003 |
| Procedure |
infusion of activated/expanded autologous t cells |
1 |
2003 |
| Biological |
infusion of allogeneic cik cells |
1 |
2007 |
| Procedure |
infusion of autologous cik cells |
1 |
2006 |
| Biological |
infusion of cd3 |
1 |
2009 |
| Biological |
infusion of cd3/cd28 stimulated t cells |
1 |
2009 |
| Procedure |
infusion of non-t-cell depleted bone marrow on day 0 |
1 |
2016 |
| Biological |
infusion of one mpc expanded cord unit |
1 |
2013 |
| Biological |
infusion of one mpc expanded cord unit/one unexpanded cord unit |
1 |
2013 |
| Biological |
infusion of two unexpanded cord blood units. |
1 |
2013 |
| Drug |
injection mecobalamin |
1 |
2018 |
| Biological |
injection of antigen-loaded cultured dendritic cells |
1 |
2009 |
| Biological |
injection of il-2-secreting cd40l-expressing autologous b-cll cells |
1 |
2003 |
| Drug |
inno-406 |
1 |
2006 |
| Drug |
inotuzumab ozogamicin-dose level 1 |
1 |
2018 |
| Drug |
inotuzumab ozogamicin-dose level 2 |
1 |
2018 |
| Drug |
inotuzumab ozogamicin (ino) |
1 |
2017 |
| Drug |
inotuzumab ozogamicin (io) |
1 |
2018 |
| Drug |
intensive chemo - ric preparation |
1 |
2011 |
| Drug |
intensive salvage therapy |
1 |
2009 |
| Drug |
interferon-alfa-2b |
1 |
2016 |
| Drug |
interferon-alpha |
1 |
2017 |
| Drug |
interferon-alpha (inf-a) |
1 |
2006 |
| Drug |
interferon-based therapy |
1 |
2019 |
| Biological |
interferon-î±-2b |
1 |
2007 |
| Biological |
interferon alfa |
1 |
2006 |
| Drug |
interferon alpha-2b (ifn-î±) 3 million units (mu) subcutaneous daily |
1 |
2014 |
| Drug |
interferon alpha 2a |
1 |
2007 |
| Drug |
interleukin-11 (il-11 |
1 |
2007 |
| Drug |
interleukin-11 (il-11/neumega) |
1 |
2007 |
| Drug |
interleukin-2 (il-2) |
1 |
2008 |
| Drug |
intermediate-dose cytarabine (idac) |
1 |
2015 |
| Drug |
intermediate-dose ia regimen |
1 |
2014 |
| Other |
intervention by caregiver |
1 |
2010 |
| Other |
interview |
1 |
2019 |
| Biological |
intranodal injection of ad-isf35 |
1 |
2009 |
| Drug |
intrathecal (it) methotrexate |
1 |
2014 |
| Drug |
intrathecal (it) triple chemotherapy prophylaxis |
1 |
2019 |
| Drug |
intrathecal methotrexate |
1 |
2009 |
| Drug |
intrathecal prophylaxis |
1 |
2005 |
| Drug |
intrathecal triple chemotherapy |
1 |
2015 |
| Drug |
intrathecal triple therapy (intrathecal cytarabine, hydrocortisone, |
1 |
2014 |
| Drug |
intrathecal triple therapy (intrathecal cytarabine, hydrocortisone,/methotrexate) |
1 |
2014 |
| Procedure |
intrathecally treatment |
1 |
2007 |
| Drug |
intravenous (iv) |
1 |
2018 |
| Drug |
intravenous (iv)/oral vitamin c |
1 |
2018 |
| Drug |
intravenous fluids |
1 |
2019 |
| Biological |
intravenous recombinant human il-15 (rhil-15) |
1 |
2011 |
| Biological |
invac-1 |
1 |
2017 |
| Drug |
investigator’s choice |
1 |
2010 |
| Combination Product |
iodine i 131 tositumomab |
1 |
2007 |
| Drug |
iomab-b |
1 |
2016 |
| Other |
ionization time of flight mass spectrometry |
1 |
2007 |
| Biological |
iov-2001 |
1 |
2019 |
| Drug |
ioversol |
1 |
2014 |
| Other |
ipad activity control group |
1 |
2014 |
| Drug |
iph2101 |
1 |
2010 |
| Drug |
iph2102 at 0.1 mg |
1 |
2012 |
| Drug |
iph2102 at 0.1 mg/kg |
1 |
2012 |
| Drug |
iph2102 at 1 mg |
1 |
2012 |
| Drug |
iph2102 at 1 mg/kg |
1 |
2012 |
| Drug |
ipi-145 (duvelisib) |
1 |
2014 |
| Drug |
irinotecan |
1 |
2000 |
| Drug |
irofulven |
1 |
1999 |
| Procedure |
irradiation (in specific conditions) |
1 |
2005 |
| Drug |
isatuximab |
1 |
2019 |
| Device |
isolex 300i |
1 |
1999 |
| Device |
isolex 300i stem cell selection |
1 |
2003 |
| Device |
isolex 300i/moabs |
1 |
1999 |
| Drug |
isolex system |
1 |
2001 |
| Other |
isotonic solution |
1 |
2010 |
| Drug |
ispinesib |
1 |
2004 |
| Device |
ithermonitor |
1 |
2015 |
| Drug |
itraconazole |
1 |
2002 |
| Biological |
itreg |
1 |
2012 |
| Drug |
iv bag protectant for moxetumomab pasudotox |
1 |
2013 |
| Drug |
iv jzp-458 |
1 |
2019 |
| Drug |
ixazomib citrate |
1 |
2015 |
| Drug |
jbh492 |
1 |
2020 |
| Drug |
jcar017 |
1 |
2018 |
| Biological |
jcar017 (lisocabtagene maraleucel) |
1 |
2017 |
| Biological |
jcar017 (lisocabtagene maraleucel) / ibrutinib |
1 |
2017 |
| Drug |
jnj-63709178 |
1 |
2016 |
| Drug |
jnj-67571244 |
1 |
2019 |
| Drug |
jnj-67856633 |
1 |
2019 |
| Drug |
jvrs-100 |
1 |
2009 |
| Drug |
k0706 capsules |
1 |
2015 |
| Biological |
kappa cd28 t cells |
1 |
2009 |
| Drug |
karonudib |
1 |
2019 |
| Drug |
keppra |
1 |
2012 |
| Drug |
kg iv on day |
1 |
2016 |
| Drug |
kg) |
1 |
2018 |
| Procedure |
kidney |
1 |
2012 |
| Drug |
klh |
1 |
2009 |
| Other |
knee extension strength |
1 |
2008 |
| Drug |
kpt-330 |
1 |
2014 |
| Drug |
krt-232 |
1 |
2019 |
| Drug |
kw-2478 |
1 |
2007 |
| Drug |
kx2-391 |
1 |
2011 |
| Drug |
l-asparaginase, erwinia asparaginase |
1 |
2005 |
| Drug |
l-phenylalanine mustard |
1 |
2007 |
| Other |
laboratory procedure |
1 |
2001 |
| Drug |
lansoprazole |
1 |
2011 |
| Drug |
larotrectinib sulfate |
1 |
2019 |
| Drug |
lbh589b |
1 |
2010 |
| Drug |
lcv |
1 |
2014 |
| Drug |
ldac (low dose cytosine arabinoside) |
1 |
2009 |
| Drug |
lenalidomida |
1 |
2009 |
| Drug |
lenalidomida/rituximab |
1 |
2009 |
| Drug |
lenalidomide (revlimidâ®) |
1 |
2009 |
| Drug |
lenalidomide / plerixafor (/ rituximab) |
1 |
2011 |
| Drug |
lenalidomide, dexamethasone |
1 |
2012 |
| Drug |
lenograstim |
1 |
2014 |
| Drug |
lenvatinib |
1 |
2019 |
| Drug |
lenzilumab |
1 |
2015 |
| Biological |
leridistim |
1 |
2000 |
| Drug |
letermovir |
1 |
2019 |
| Drug |
leucomax |
1 |
2007 |
| Procedure |
leukapheresis/collection of pbmcs |
1 |
2013 |
| Procedure |
leukemia cell harvest |
1 |
2007 |
| Biological |
leukemia cell vaccine |
1 |
2008 |
| Other |
leukemic |
1 |
1999 |
| Other |
leukemic/stroma cells |
1 |
1999 |
| Drug |
leuprolide |
1 |
2011 |
| Dietary Supplement |
levocarnitine |
1 |
2018 |
| Drug |
levofloxacin |
1 |
2011 |
| Drug |
lfb-r603 |
1 |
2010 |
| Drug |
lgh447 |
1 |
2014 |
| Drug |
lgh447 / midostaurin |
1 |
2014 |
| Drug |
lintuzumab (sgn-33) |
1 |
2007 |
| Drug |
lintuzumab ac 225 |
1 |
2018 |
| Drug |
liposomal amphotericine b |
1 |
2006 |
| Drug |
liposomal arac |
1 |
2014 |
| Drug |
liposomal cytarabine |
1 |
1999 |
| Drug |
liposome-encapsulated cytarabine (depocyte) |
1 |
2008 |
| Drug |
lirilumab |
1 |
2015 |
| Drug |
lomustine |
1 |
2007 |
| Drug |
lomustine, intermediate dose cytarabine |
1 |
2007 |
| Drug |
lonafarnib (sch66336) |
1 |
2002 |
| Drug |
lorvotuzumab mertansine (imgn901) |
1 |
2015 |
| Drug |
low-dose cytarabine (ldac) |
1 |
2015 |
| Drug |
low-dose methotrexate |
1 |
2013 |
| Drug |
low dose 5’-azacitidine |
1 |
2013 |
| Drug |
low dose il-2 |
1 |
2019 |
| Drug |
low dose total body irradiation (ld tbi) |
1 |
2011 |
| Behavioral |
low glycemic index diet |
1 |
2017 |
| Drug |
loxo-305 |
1 |
2018 |
| Drug |
luitpold azacitidine |
1 |
2011 |
| Biological |
lumiliximab |
1 |
2003 |
| Drug |
lumiliximab with fcr |
1 |
2005 |
| Drug |
ly2090314 |
1 |
2010 |
| Drug |
ly2181308 sodium |
1 |
2008 |
| Drug |
ly2510924 |
1 |
2016 |
| Drug |
ly2874455 |
1 |
2017 |
| Drug |
ly573636-sodium |
1 |
2008 |
| Procedure |
lymph node biopsy |
1 |
2008 |
| Drug |
lymphocyte injection of prophylactic donor (pdli) |
1 |
2016 |
| Drug |
lymphodepleting |
1 |
2018 |
| Drug |
lymphodepletion with cyclophosphamide |
1 |
2015 |
| Drug |
lymphodepletion with fludarabine |
1 |
2015 |
| Drug |
m2 i.v. |
1 |
2009 |
| Drug |
m2 x 1 |
1 |
2016 |
| Drug |
m2 x 2 |
1 |
2016 |
| Drug |
mab 216 |
1 |
2006 |
| Other |
magnetic affinity cell sorting |
1 |
2009 |
| Procedure |
magnetic resonance imaging |
1 |
2015 |
| Dietary Supplement |
manuka honey |
1 |
2018 |
| Drug |
maraviroc |
1 |
2014 |
| Drug |
marqibo |
1 |
2016 |
| Drug |
marqiboâ® (vincristine sulfate liposomes injection) |
1 |
2007 |
| Procedure |
marrow transplant (bmt) |
1 |
2019 |
| Procedure |
massage therapy |
1 |
2010 |
| placebo |
matched placebo |
1 |
2019 |
| Other |
matrix-assisted laser desorption |
1 |
2007 |
| Other |
matrix-assisted laser desorption/ionization time of flight mass spectrometry |
1 |
2007 |
| Drug |
max-40279 |
1 |
2018 |
| Biological |
mb-102 |
1 |
2019 |
| Biological |
mb-cart19.1 |
1 |
2019 |
| Drug |
mcla-117 bispecific antibody |
1 |
2017 |
| Drug |
mdm2 inhibitor krt-232 |
1 |
2017 |
| Biological |
mdx-1342 |
1 |
2008 |
| Drug |
mec |
1 |
2008 |
| Drug |
medi-551 |
1 |
2011 |
| Procedure |
mediastinal irradiation |
1 |
2005 |
| Procedure |
mediastinal irradiation (if residual tu) |
1 |
2005 |
| Procedure |
mediastinal irradiation (if residual tumor) |
1 |
2005 |
| Procedure |
megadose of cd34 selected progenitor cells |
1 |
2002 |
| Drug |
megestrol acetate |
1 |
2003 |
| Drug |
mek 162 |
1 |
2014 |
| Drug |
melfalan in conditioning before transplantation |
1 |
2009 |
| Drug |
melphalan, atg, fludarabine |
1 |
2005 |
| Drug |
melphalan/bortezomib |
1 |
2008 |
| Drug |
memory t cell selection |
1 |
2019 |
| Drug |
men1112 |
1 |
2015 |
| Drug |
men1703 |
1 |
2016 |
| Drug |
mercaptopurine oral suspension |
1 |
2019 |
| Drug |
mercaptopurine, imatinib |
1 |
2005 |
| Drug |
merestinib |
1 |
2017 |
| Procedure |
mesenchymal stem cell transplantation |
1 |
2014 |
| Biological |
mesenchymal stem cells |
1 |
2010 |
| Drug |
mesylate imatinib capsule |
1 |
2013 |
| Drug |
metformin hydrochloride |
1 |
2016 |
| Drug |
methotrexate (arm with bortezomib) |
1 |
2014 |
| Drug |
methotrexate (arm with maraviroc) |
1 |
2014 |
| Drug |
methotrexate (intrathecal administration) |
1 |
2018 |
| Drug |
methotrexate (intravenous administration) |
1 |
2018 |
| Drug |
methotrexate (low dose) |
1 |
2013 |
| Drug |
methotrexate oral product |
1 |
2018 |
| Drug |
methotrexate sodium |
1 |
2014 |
| Drug |
methotrexate) |
1 |
2014 |
| Drug |
methotrexate, cyclophosphamide, cytarabine, etoposide |
1 |
2005 |
| Drug |
methotrexate, teniposide, peg-asparaginase |
1 |
2005 |
| Drug |
methotrexate/hydrocortisone |
1 |
2005 |
| Drug |
methotrexate/hydrocortisone/cytarabine |
1 |
2014 |
| Drug |
methoxyamine |
1 |
2012 |
| Drug |
methylprednisone |
1 |
2009 |
| Drug |
metotrexate |
1 |
2014 |
| Drug |
metronidazole, clarithromycin, ciprofloxacin |
1 |
2011 |
| Drug |
metronidazole, clarithromycin, ciprofloxacin/lansoprazole |
1 |
2011 |
| Drug |
mgta 456 infusion |
1 |
2018 |
| Other |
microbiological analysis |
1 |
2011 |
| Biological |
microtransplantation |
1 |
2016 |
| Drug |
midazolam |
1 |
2013 |
| Drug |
midostaurin (pkc412) |
1 |
2008 |
| placebo |
midostaurin placebo |
1 |
2018 |
| Drug |
milademetan tosylate |
1 |
2018 |
| Procedure |
mild soap skin cleanser |
1 |
2013 |
| Device |
miltenyi biotec clinimacs device |
1 |
2008 |
| Device |
miltenyi clinimacs |
1 |
2005 |
| Device |
miltenyi magnetic cell sorter for cd3 |
1 |
2009 |
| Device |
miltenyi reagent system |
1 |
2006 |
| Combination Product |
miltenyi system |
1 |
2007 |
| Drug |
minnelide |
1 |
2018 |
| Drug |
minus total body irradiation (low dose) |
1 |
2011 |
| Drug |
mitomycin c |
1 |
1999 |
| Drug |
mitoxantrone / etoposide / gemtuzumab ozogamicin |
1 |
2019 |
| Drug |
mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine |
1 |
2005 |
| Drug |
mitoxantrone, cytarabine |
1 |
2017 |
| Drug |
mitoxantrone, etoposide |
1 |
2018 |
| Drug |
mitoxantrone, etoposide/cytarabine |
1 |
2018 |
| Drug |
mitozantrone |
1 |
2004 |
| Drug |
mitozantrone, etoposide, cytarabine (combination chemotherapy) |
1 |
2004 |
| Drug |
mk-4827 |
1 |
2008 |
| Drug |
mk-8628 |
1 |
2012 |
| Drug |
mk0457 |
1 |
2005 |
| Dietary Supplement |
ml) |
1 |
2012 |
| Drug |
mlm-car44.1 t-cells, cyclophosphamide |
1 |
2019 |
| Drug |
mlm-car44.1 t-cells, cyclophosphamide/fludarabine from -5 to -3 |
1 |
2019 |
| Drug |
mln 9708 |
1 |
2014 |
| Drug |
mln518 |
1 |
2006 |
| Device |
moabs |
1 |
1999 |
| Procedure |
mobilized peripheral blood stem cell graft with tacrolimus |
1 |
2019 |
| Procedure |
mobilized peripheral blood stem cell graft with tacrolimus/methotrexate |
1 |
2019 |
| Procedure |
mobilized peripheral blood stem cell graft with tacrolimus/mycophenolate mofetil/post-transplant cyclophosphamide |
1 |
2019 |
| Drug |
modified bone marrow stem cell transplantation |
1 |
1999 |
| Drug |
modified bucy |
1 |
2017 |
| Behavioral |
modified geriatric assessment (mga) |
1 |
2019 |
| Behavioral |
modified strength training |
1 |
2017 |
| Biological |
mogamulizumab |
1 |
2019 |
| Biological |
monoclonal antibody a27.15 |
1 |
1999 |
| Biological |
monoclonal antibody cd19 |
1 |
1999 |
| Biological |
monoclonal antibody cd20 |
1 |
1999 |
| Biological |
monoclonal antibody e2.3 |
1 |
1999 |
| Biological |
monoclonal antibody mik-beta-1 |
1 |
2001 |
| Biological |
montanide adjuvant |
1 |
2007 |
| Drug |
montelukast |
1 |
2019 |
| Biological |
mor00208 |
1 |
2013 |
| Drug |
morphine |
1 |
2019 |
| Drug |
morphine sulfate |
1 |
1999 |
| Drug |
moxetumomab pasudotox |
1 |
2013 |
| Drug |
moxetumomab pasudotox-tdfk |
1 |
2019 |
| Drug |
moxetumomab pasudotox (cat 8015) |
1 |
2007 |
| Combination Product |
mrd-directed therapy |
1 |
2016 |
| Other |
mri pelvic |
1 |
2018 |
| Drug |
ms-533 |
1 |
2018 |
| Drug |
msc2490484a (m3814) |
1 |
2014 |
| Drug |
mt-3724 phase 1 |
1 |
2015 |
| Drug |
mt-3724 phase 2 |
1 |
2015 |
| Biological |
muc1 |
1 |
2017 |
| Biological |
muc1/cll1/cd33/cd38/cd56/cd123-specific gene-engineered t cells |
1 |
2017 |
| Drug |
multikinase inhibitor at9283 |
1 |
2011 |
| Other |
multiplex respiratory viral pcr |
1 |
2013 |
| Biological |
multistemâ® |
1 |
2008 |
| Dietary Supplement |
multivitamin |
1 |
2018 |
| Biological |
murine autologous anti-cd19 chimeric antigen receptor t cells |
1 |
2020 |
| Drug |
muromonab |
1 |
2007 |
| Behavioral |
music imagery |
1 |
2004 |
| Procedure |
music therapy |
1 |
2006 |
| Drug |
mvpd |
1 |
2009 |
| Drug |
mvpdl |
1 |
2011 |
| Drug |
mycophenolate |
1 |
2011 |
| Drug |
mycophenylate mofetil |
1 |
2013 |
| Drug |
myeloablative allogeneic hct with a non-tbi conditioning regimen |
1 |
2018 |
| Drug |
myeloablative conditioning regimen |
1 |
2015 |
| Procedure |
myeloablative haploidentical stem cell transplant |
1 |
2012 |
| Procedure |
myeloid progenitor cell transplantation |
1 |
2014 |
| Drug |
mylotarg (gemtuzumab ozogamicin) injection |
1 |
2002 |
| Drug |
mylotarg associated with conventional chemotherapy (arac |
1 |
2009 |
| Drug |
mylotarg associated with conventional chemotherapy (arac / daunorubicin), |
1 |
2009 |
| Other |
mylotarg purging before autologous pbsc transplantation |
1 |
2012 |
| Drug |
nalbuphine |
1 |
2019 |
| Drug |
native l asparaginase |
1 |
2008 |
| Biological |
natural killer (nk) cell infusion |
1 |
2011 |
| Procedure |
natural killer (nk) cell transplant |
1 |
2005 |
| Biological |
natural killer (nk) cells |
1 |
2016 |
| Drug |
nedisertib |
1 |
2019 |
| Drug |
nelarabine injection 1000mg |
1 |
2006 |
| Drug |
nelarabine injection 1000mg/m2 |
1 |
2006 |
| Drug |
nelarabine injection 1500mg |
1 |
2006 |
| Drug |
nelarabine injection 1500mg/m2 |
1 |
2006 |
| Drug |
nelarabine injection 400mg |
1 |
2006 |
| Drug |
nelarabine injection 400mg/m2 |
1 |
2006 |
| Drug |
nelarabine injection 650mg |
1 |
2006 |
| Drug |
nelarabine injection 650mg/m2 |
1 |
2006 |
| Drug |
nelfinavir mesylate |
1 |
2010 |
| Drug |
nerofe |
1 |
2017 |
| Biological |
neukoplastâ„¢ (nk-92) |
1 |
2009 |
| Drug |
neumega) |
1 |
2007 |
| Other |
neutropenic diet |
1 |
2008 |
| Drug |
nexavar (sorafenib, bay43-9006) |
1 |
2008 |
| Diagnostic Test |
ngs-mrd |
1 |
2018 |
| Drug |
nicordâ® (omidubicel) |
1 |
2016 |
| Other |
nih toolbox flanker inhibitory control |
1 |
2019 |
| Other |
nih toolbox flanker inhibitory control/attention test |
1 |
2019 |
| Other |
nih toolbox list sorting working memory test |
1 |
2019 |
| Drug |
nilotinib / lde225 |
1 |
2011 |
| Drug |
nilotinib 400 mg bid |
1 |
2015 |
| Drug |
nilotinib followed by treatment-free |
1 |
2013 |
| Drug |
nilotinib, interferon-alfa |
1 |
2010 |
| Drug |
nilotinib, pegylated interferon alpha-2b, imatinib |
1 |
2013 |
| Drug |
nilotinib,novartis,300 mg twice a day |
1 |
2011 |
| Drug |
nilotinib,novartis,300 mg twice a day /pegylated interferon 2a,roche, 45 microg weekly starting month 2-month 12/beyond according to investigator choice. |
1 |
2011 |
| Drug |
nilotinib/mvpd |
1 |
2009 |
| Drug |
nintedanib/aml induction |
1 |
2016 |
| Drug |
nivolumab (.25 mg |
1 |
2018 |
| Drug |
nivolumab (.25 mg/kg) |
1 |
2018 |
| Drug |
nivolumab (.5 mg |
1 |
2018 |
| Drug |
nivolumab (.5 mg/kg) |
1 |
2018 |
| Biological |
nk cell |
1 |
2017 |
| Procedure |
nk cell infusion: |
1 |
2011 |
| Biological |
nk cells / chemotherapy starting |
1 |
2016 |
| Drug |
nms-03592088 |
1 |
2019 |
| Other |
no dli |
1 |
2010 |
| Dietary Supplement |
no high phenolic evoo intake |
1 |
2019 |
| Other |
no systemic anticoagulant prophylaxis |
1 |
2015 |
| Drug |
non-myeloablative allogeneic stem cell transplant with prophylactic activated dli |
1 |
2006 |
| Procedure |
non-tbi regime |
1 |
2015 |
| Procedure |
nonmyeloablative allogeneic hsct |
1 |
2008 |
| Drug |
not |
1 |
2014 |
| Drug |
notch signalling pathway inhibitor ro4929097 |
1 |
2010 |
| Drug |
nox-a12 |
1 |
2011 |
| Biological |
npmw-peptide vaccine |
1 |
2016 |
| Dietary Supplement |
nutrinidrink |
1 |
2012 |
| Dietary Supplement |
nutrinidrink/fortini mf unflavoured (1.5kcal/ml) |
1 |
2012 |
| Dietary Supplement |
nutritional intervention |
1 |
2013 |
| Drug |
o g-csf) |
1 |
2015 |
| Drug |
oblimersen-rituximab-fludarabine |
1 |
2004 |
| Drug |
oblimerson sodium, g3139 |
1 |
2001 |
| Drug |
odsh |
1 |
2013 |
| Drug |
ofatumumab (gsk1841157) infusion |
1 |
2012 |
| Drug |
ofatumumab / fresh frozen plasma |
1 |
2012 |
| Drug |
ofatumumab 100 mg, 1000 mg |
1 |
2010 |
| Drug |
ofatumumab 100 mg, 1000 mg / vial |
1 |
2010 |
| Drug |
ofatumumab with gsk2110183 |
1 |
2012 |
| Drug |
ofatumumab/dexamethasone |
1 |
2011 |
| Drug |
ofatumumab/hdmp |
1 |
2010 |
| Drug |
ofc infusion |
1 |
2009 |
| Other |
off therapy |
1 |
2012 |
| Drug |
olaparib |
1 |
2019 |
| Dietary Supplement |
olive oil |
1 |
2018 |
| Drug |
omacetaxine |
1 |
2011 |
| Drug |
omega-3 fatty acids |
1 |
2015 |
| Drug |
omegaven |
1 |
2013 |
| Drug |
on01910 na |
1 |
2009 |
| Drug |
oncaspar |
1 |
2012 |
| Biological |
oncoquest-cll vaccine |
1 |
2013 |
| Procedure |
one expanded cord blood unit |
1 |
2003 |
| Biological |
one unexpanded cord unit |
1 |
2013 |
| Procedure |
one unmanipulated |
1 |
2003 |
| Procedure |
one unmanipulated/one expanded cord blood unit |
1 |
2003 |
| Drug |
ono |
1 |
2012 |
| Drug |
ono-7475 |
1 |
2017 |
| Drug |
ono/gs-4059 |
1 |
2012 |
| Drug |
ontak |
1 |
2003 |
| Drug |
ontak (denileukin diftitox) |
1 |
2007 |
| Drug |
onvansertib |
1 |
2017 |
| Drug |
opb-111077 |
1 |
2017 |
| Drug |
opb-51602 |
1 |
2011 |
| Drug |
open label lam-003 |
1 |
2018 |
| Combination Product |
optimal medical treatment |
1 |
2018 |
| Biological |
or cd123-specific car gene-engineered t cells |
1 |
2019 |
| Drug |
oral arsenic trioxide |
1 |
2018 |
| Drug |
oral sodium phenylbutyrate |
1 |
2000 |
| Drug |
oral vitamin c |
1 |
2018 |
| Biological |
orcagraft |
1 |
2019 |
| Drug |
osi-461 |
1 |
2003 |
| Drug |
ots167iv |
1 |
2016 |
| Drug |
otx015 |
1 |
2012 |
| Drug |
otx015/mk-8628 |
1 |
2012 |
| Behavioral |
outpatient care model |
1 |
2019 |
| Drug |
oxidative phosphorylation inhibitor iacs-010759 |
1 |
2016 |
| Biological |
p.dom-wt1-126 dna vaccine |
1 |
2011 |
| Biological |
p.dom-wt1-37 dna vaccine |
1 |
2011 |
| Biological |
p.dom-wt1-37 dna vaccine/p.dom-wt1-126 dna vaccine |
1 |
2011 |
| Drug |
p1101 |
1 |
2013 |
| Behavioral |
pace call |
1 |
2010 |
| Behavioral |
pace call/fit4life |
1 |
2010 |
| Drug |
pacritinib |
1 |
2014 |
| Drug |
pad-vcd |
1 |
2016 |
| Drug |
palbociclib oral capsule |
1 |
2018 |
| Drug |
palcociclib |
1 |
2019 |
| Other |
palliative care intervention |
1 |
2015 |
| Drug |
panobinostat (lbh589) |
1 |
2009 |
| Drug |
panobinostat (lbh589)/5-azacytidine |
1 |
2009 |
| Drug |
panobinostat/lbh589 |
1 |
2009 |
| Drug |
panobinostat/lbh589b |
1 |
2010 |
| Biological |
patient-derived cd19- |
1 |
2017 |
| Biological |
patient-derived cd19-/cd22 specific car |
1 |
2017 |
| Biological |
patient-derived cd22-specific car t-cells also expressing an egfrt |
1 |
2017 |
| Biological |
patient derived cd19 specific car t cells also expressing an egfrt |
1 |
2014 |
| Other |
patient observation |
1 |
2018 |
| Drug |
pazopanib |
1 |
2011 |
| Genetic |
pbcar0191 |
1 |
2018 |
| Genetic |
pbcar20a |
1 |
2019 |
| Biological |
pbsc |
1 |
2000 |
| Procedure |
pbsc graft |
1 |
2018 |
| Procedure |
pbsc transplant |
1 |
2011 |
| Procedure |
pbsct |
1 |
2006 |
| Drug |
pci 32765 |
1 |
2011 |
| Combination Product |
pd-l1, pd-l2 peptides with montanide isa51 |
1 |
2019 |
| Drug |
pdr001 |
1 |
2017 |
| Biological |
pediacelâ® |
1 |
2015 |
| Drug |
peg-alpha interferon (peg-intron) |
1 |
2002 |
| Drug |
peg-asp |
1 |
2014 |
| Drug |
peg-g-csf |
1 |
2017 |
| Drug |
peg-ifn-î± |
1 |
2014 |
| Drug |
peg-interferon |
1 |
2005 |
| Drug |
peg-interferon alpha2b |
1 |
2013 |
| Drug |
peg-l-asparaginase cons |
1 |
2013 |
| Drug |
peg-l-asparaginase ind |
1 |
2013 |
| Drug |
peg asparaginase |
1 |
2019 |
| Drug |
peg asparaginase at six weeks interval |
1 |
2009 |
| Drug |
peg asparaginase at two weeks interval |
1 |
2009 |
| Drug |
peg interferon alpha 2b (peg intron) |
1 |
2006 |
| Drug |
pegaspargase 1250 iu |
1 |
2016 |
| Drug |
pegaspargase 1250 iu/m2 x 2 |
1 |
2016 |
| Drug |
pegaspargase 2500 iu |
1 |
2016 |
| Drug |
pegaspargase 2500 iu/m2 x 1 |
1 |
2016 |
| Drug |
pegifn |
1 |
2012 |
| Drug |
peginterferon-î±-2a |
1 |
2015 |
| Drug |
peginterferon alfa-2a |
1 |
2016 |
| Drug |
peginterferon î±2b |
1 |
2012 |
| Drug |
pegylated-proline-interferon alpha-2b |
1 |
2017 |
| Drug |
pegylated asparaginase |
1 |
2008 |
| Drug |
pegylated interferon |
1 |
2010 |
| Drug |
pegylated interferon-alfa-2b |
1 |
2016 |
| Drug |
pegylated interferon 2a,roche, 45 microg weekly starting month 2-month 12 |
1 |
2011 |
| Drug |
pegylated interferon alfa-2a |
1 |
2016 |
| Drug |
pegylated l-asparaginase |
1 |
2017 |
| Drug |
pegylated liposomal doxorubicin hydrochloride |
1 |
1999 |
| Drug |
pembrolizumab, |
1 |
2016 |
| Drug |
pemetrexed |
1 |
2007 |
| Drug |
pentetic acid calcium |
1 |
2001 |
| Drug |
pentoxifylline |
1 |
2015 |
| Drug |
pentoxifylline/chemotherapy |
1 |
2015 |
| Biological |
peptide specific dendritic cell |
1 |
2017 |
| Procedure |
peripheral blood for correlative studies |
1 |
2013 |
| Procedure |
peripheral blood hematopoietic cell transplantation (hct) |
1 |
2017 |
| Procedure |
peripheral blood progenitor cell transplant |
1 |
1999 |
| Procedure |
peripheral blood stem cell transplantation (pbsct) |
1 |
2011 |
| Biological |
peripheral blood stem cells |
1 |
2016 |
| Procedure |
peripheral blood transplant |
1 |
2018 |
| Drug |
pertuzumab |
1 |
2019 |
| Diagnostic Test |
pet-ct scan |
1 |
2018 |
| Device |
pet scans |
1 |
2013 |
| Drug |
pevonedistat (baml-16-001-s9) |
1 |
2016 |
| Drug |
pevonedistat 10 mg |
1 |
2016 |
| Drug |
pevonedistat 10 mg/m^2 |
1 |
2016 |
| Drug |
pevonedistat 20 mg |
1 |
2016 |
| Drug |
pevonedistat 20 mg/m^2 |
1 |
2016 |
| Drug |
pevonedistat 25 mg |
1 |
2016 |
| Drug |
pevonedistat 25 mg/m^2 |
1 |
2016 |
| Drug |
pevonedistat 44 mg |
1 |
2016 |
| Drug |
pevonedistat 44 mg/m^2 |
1 |
2016 |
| Drug |
pf-03084014 |
1 |
2009 |
| Drug |
pf-04449913 (glasdegib) |
1 |
2015 |
| Drug |
pf-114 |
1 |
2016 |
| Drug |
pgx-odsh-2013-aml-1 |
1 |
2014 |
| Behavioral |
pharmaceutical care |
1 |
2017 |
| Behavioral |
pharmaceutical care/adherence aids |
1 |
2017 |
| Other |
pharmacodynamic study |
1 |
2013 |
| Genetic |
pharmacogenomics |
1 |
2015 |
| Drug |
phenytoin |
1 |
2005 |
| Other |
phosphate-buffered saline (pbs) |
1 |
2006 |
| Drug |
photopheresis |
1 |
2002 |
| Other |
physical activity adapted program |
1 |
2019 |
| Behavioral |
physical activity counselor |
1 |
2014 |
| Behavioral |
physical therapy |
1 |
2009 |
| Drug |
physicians’ choice |
1 |
2011 |
| Drug |
pioglitazone / tki |
1 |
2016 |
| Drug |
piperacillin-tazobactam |
1 |
1999 |
| Drug |
piperacillin sodium |
1 |
1999 |
| Drug |
pixantrone iv infusion |
1 |
2005 |
| placebo |
placebo (normal saline solution) |
1 |
2012 |
| Drug |
placebo / cytarabine |
1 |
2010 |
| placebo |
placebo for ag-120 |
1 |
2019 |
| placebo |
placebo for ag-221 |
1 |
2019 |
| placebo |
placebo to match ibrutinib |
1 |
2016 |
| placebo |
placebo with azacitidine |
1 |
2017 |
| Drug |
placebo/chemotherapy |
1 |
2015 |
| Procedure |
planar scintigraphy imaging |
1 |
2011 |
| Drug |
plerixafor ( |
1 |
2011 |
| Drug |
plerixafor dose escalation |
1 |
2011 |
| Drug |
plx2853 |
1 |
2018 |
| Drug |
pm01183 1 mg powder for concentrate for solution for infusion |
1 |
2011 |
| Drug |
pm01183 1 mg powder for concentrate for solution for infusion/pm01183 4 mg powder for concentrate for solution for infusion |
1 |
2011 |
| Drug |
pm01183 4 mg powder for concentrate for solution for infusion |
1 |
2011 |
| Biological |
pneumococcal polyvalent vaccine |
1 |
2011 |
| Biological |
pneumococcal vaccine |
1 |
2006 |
| Drug |
pneumovax |
1 |
2013 |
| Biological |
pneumovaxâ® 23 |
1 |
2015 |
| Drug |
pol6326 |
1 |
2011 |
| Drug |
polatuzumab vedotin |
1 |
2011 |
| Biological |
polyphenon e |
1 |
2005 |
| Drug |
ponatinib - phase 1 |
1 |
2012 |
| Drug |
ponatinib - phase 2 |
1 |
2012 |
| Drug |
ponatinib 15 mg |
1 |
2015 |
| Drug |
ponatinib 15 mg qd |
1 |
2015 |
| Drug |
ponatinib 30 mg |
1 |
2015 |
| Drug |
ponatinib 30 mg qd |
1 |
2015 |
| Drug |
ponatinib 45 mg |
1 |
2015 |
| Drug |
posaconazole oral suspensions |
1 |
2019 |
| Drug |
posology dose modification |
1 |
2016 |
| Drug |
possible reinitiation treatment: ibrutinib |
1 |
2017 |
| Drug |
possible reinitiation treatment: ibrutinib / venetoclax 12 cycles |
1 |
2017 |
| Drug |
post-chlorambucil therapy follow-up |
1 |
2012 |
| Drug |
post-hct cyclophosphamide 50mg |
1 |
2016 |
| Drug |
post-hct cyclophosphamide 50mg/kg iv on day/3, /4 |
1 |
2016 |
| Drug |
post-hct mesna |
1 |
2016 |
| Procedure |
post-transplant cyclophosphamide |
1 |
2019 |
| Behavioral |
postremission consolidation based on mrd status |
1 |
2006 |
| Biological |
pr1 leukemia peptide vaccine |
1 |
2000 |
| Biological |
pr1:169-177 peptide |
1 |
2007 |
| Drug |
pralatraxate, |
1 |
2018 |
| Drug |
pralatrexate |
1 |
2012 |
| Biological |
prame vaccination |
1 |
2015 |
| Drug |
pre-dli salvage chemotherapy |
1 |
2011 |
| Drug |
pre-hct mesna on days -2 |
1 |
2016 |
| Drug |
pre-hct mesna on days -2/-1 |
1 |
2016 |
| Drug |
pre-hct mesna on days -5 |
1 |
2016 |
| Drug |
pre-hct mesna on days -5/-4 |
1 |
2016 |
| Drug |
pre-hct mesna on days -6 |
1 |
2016 |
| Drug |
pre-hct mesna on days -6/-5 |
1 |
2016 |
| Drug |
prednison, vincristine, cytarabine, methotrexate, etoposide, cyclophosphamide, doxorubicin |
1 |
2005 |
| Drug |
prednisone pill |
1 |
2019 |
| Drug |
prednisone, dexamethasone, vincristine, daunorubicin |
1 |
2005 |
| Drug |
prednisone, vincristine, daunorubicin, peg-l-asparaginase, erwinia l-asparaginase, doxorubicin, cyclophosphamide, cytarabine, thioguanine |
1 |
2007 |
| Drug |
prevenar 13 |
1 |
2013 |
| Drug |
prevention of gvhd |
1 |
2016 |
| Biological |
prevnarâ®13 |
1 |
2015 |
| Drug |
prexasertib |
1 |
2016 |
| Drug |
prgn-3006 t cells |
1 |
2019 |
| Drug |
pri-724 |
1 |
2012 |
| Drug |
primary antifungal prophylaxis |
1 |
2018 |
| Drug |
procrit |
1 |
2008 |
| Drug |
procrit (epoetin alfa) |
1 |
2010 |
| Behavioral |
promoting resilience in stress management (prism) |
1 |
2015 |
| Procedure |
prophylactic gpbpci |
1 |
2011 |
| Biological |
prophylactic platelet transfusion |
1 |
2007 |
| Drug |
propofol-fentanyl |
1 |
2005 |
| Drug |
propofol alone |
1 |
2005 |
| Other |
proteosome inhibition assessment |
1 |
2010 |
| Biological |
protmune |
1 |
2016 |
| Procedure |
protocol ii-ida |
1 |
2005 |
| Drug |
ps-341 |
1 |
2005 |
| Drug |
psc-833 |
1 |
1999 |
| Drug |
psoralen |
1 |
2000 |
| Other |
psychological intervention |
1 |
2017 |
| Drug |
ptc299 |
1 |
2018 |
| Drug |
ptk 787 (vatalanib) |
1 |
2004 |
| Drug |
ptx-200 |
1 |
2016 |
| Drug |
pyrimethamine |
1 |
2010 |
| Drug |
pyroxamide |
1 |
2002 |
| Drug |
pz01 car-t cells |
1 |
2017 |
| Biological |
qs21 |
1 |
1999 |
| Other |
quality-of-life |
1 |
2016 |
| Other |
quality of life assessment |
1 |
2012 |
| Procedure |
r-blocks |
1 |
2005 |
| Drug |
r-chop |
1 |
2018 |
| Drug |
r( |
1 |
2004 |
| Drug |
r(/)xk469 |
1 |
2004 |
| Drug |
rabbit anti-human t-lymphocyte globulin |
1 |
2017 |
| Biological |
rabbit anti-thymocyte globulin (atg) |
1 |
2007 |
| Device |
rabbit antithymocyte globulin |
1 |
2018 |
| Drug |
rad001 |
1 |
2004 |
| Radiation |
radiation |
1 |
2015 |
| Radiation |
radiation therapy (rt) |
1 |
2000 |
| Radiation |
radioimmunotherapy |
1 |
1999 |
| Drug |
radotinib hcl |
1 |
2018 |
| Drug |
raltegravir |
1 |
2009 |
| Drug |
raltitrexed |
1 |
1999 |
| Drug |
randomisation course 1 mitoxantrone versus daunoxome |
1 |
2013 |
| Drug |
randomisation course 2 adxe versus fladx |
1 |
2013 |
| Drug |
randomization between two established chemotherapies |
1 |
2005 |
| Drug |
rapamycin / mec |
1 |
2008 |
| Drug |
rapamycin, mitoxantrone, etoposide, cytarabine |
1 |
2008 |
| Dietary Supplement |
rapeseed oil |
1 |
2019 |
| Drug |
ravuconazole |
1 |
2003 |
| Device |
reagent system |
1 |
2014 |
| Drug |
realgar-indigo naturalis formula |
1 |
2016 |
| Biological |
recombinant 70-kd heat-shock protein |
1 |
2002 |
| Biological |
recombinant ephb4-hsa fusion protein |
1 |
2018 |
| Biological |
recombinant human thrombopoietin |
1 |
2000 |
| Drug |
recombinant interferon alfa 2a |
1 |
2016 |
| Biological |
recombinant interleukin-3 |
1 |
2000 |
| Biological |
recwt1-a10 |
1 |
2013 |
| Biological |
recwt1-a10/as01b |
1 |
2013 |
| Biological |
red blood cell transfusion |
1 |
2014 |
| Drug |
reduced-intensity conditioning regimen |
1 |
2015 |
| Procedure |
reduced intensity conditioning stem cell transplantation |
1 |
2006 |
| Procedure |
reduced intensity haplodentical stem cell transplant |
1 |
2012 |
| Biological |
regulatory t cells (treg) |
1 |
2012 |
| Drug |
relapse |
1 |
2017 |
| Biological |
related |
1 |
2016 |
| Biological |
related/unrelated bone marrow cells |
1 |
2016 |
| Behavioral |
relaxation education |
1 |
2014 |
| Other |
respiratory training |
1 |
2019 |
| Behavioral |
resting vitals |
1 |
2007 |
| Drug |
rft5-smpt-dga |
1 |
2001 |
| Drug |
rgel |
1 |
2002 |
| Drug |
rhtpo |
1 |
2019 |
| Drug |
ribociclib |
1 |
2018 |
| Drug |
rif |
1 |
2014 |
| Drug |
rigosertib |
1 |
2010 |
| Other |
risk-adapted, mrd-directed therapy |
1 |
2011 |
| Behavioral |
risk-oriented consolidation |
1 |
2006 |
| Drug |
ritonavir |
1 |
2016 |
| Drug |
rituxan |
1 |
2003 |
| Drug |
rituxanâ„¢ |
1 |
2007 |
| Drug |
rituximab / idec-c2b8 |
1 |
2014 |
| Drug |
rituximab [mabthera] |
1 |
2011 |
| Drug |
rituximab for patients with b-cell malignancies |
1 |
2006 |
| Drug |
rituximab injection |
1 |
2020 |
| Drug |
rituximab) |
1 |
2011 |
| Drug |
rituximab, methylprednisolone |
1 |
2007 |
| Drug |
rituximab, vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-c |
1 |
2012 |
| Drug |
rituximab/hyaluronidase human |
1 |
2018 |
| Drug |
rituximab/mvpdl |
1 |
2011 |
| Biological |
rivogenlecleucel |
1 |
2018 |
| Genetic |
rna analysis |
1 |
2007 |
| Drug |
ro5045377 |
1 |
2012 |
| Drug |
ro5429083 |
1 |
2012 |
| Drug |
ro5503781 |
1 |
2011 |
| Drug |
ro5503781 mbp |
1 |
2013 |
| Drug |
ro5503781 sdp |
1 |
2013 |
| Drug |
ro6839921 |
1 |
2014 |
| Drug |
ro6870810 |
1 |
2014 |
| Drug |
roferon-a |
1 |
1999 |
| Drug |
ropeginterferon |
1 |
2019 |
| Drug |
routine reduction of immunosuppressive drugs(cyclosporine) |
1 |
2017 |
| Drug |
s 055746 |
1 |
2016 |
| Drug |
s 55746 |
1 |
2016 |
| Combination Product |
s 64315 (also referred as mik665) |
1 |
2018 |
| Combination Product |
s 64315 (also referred as mik665)/venetoclax |
1 |
2018 |
| Drug |
s64315 once a week |
1 |
2016 |
| Drug |
s64315 twice a week |
1 |
2016 |
| Drug |
s65487 |
1 |
2018 |
| Drug |
saline |
1 |
2018 |
| Drug |
salvage chemotherapy |
1 |
2014 |
| Dietary Supplement |
salvia hispanica seed |
1 |
2016 |
| Biological |
samalizumab (baml-16-001-s1) |
1 |
2016 |
| Drug |
sapacitabine/decitabine (part 1 - completed) |
1 |
2010 |
| Drug |
sapacitabine/venetoclax (part 2 - recruiting) |
1 |
2010 |
| Drug |
sapanisertib |
1 |
2015 |
| Drug |
sar103168 |
1 |
2009 |
| Drug |
sar245409 |
1 |
2011 |
| Drug |
sar440234 |
1 |
2018 |
| Drug |
sb1518 |
1 |
2008 |
| Drug |
sb939 |
1 |
2010 |
| Drug |
sc-peg |
1 |
2012 |
| Drug |
sc-peg e. coli l-asparaginase |
1 |
2010 |
| Drug |
sch66336 |
1 |
2002 |
| Biological |
scri-hucar19v1 |
1 |
2018 |
| Procedure |
sct |
1 |
2012 |
| Drug |
second-line ibrutinib |
1 |
2012 |
| Procedure |
second allogeneic bone marrow transplantation |
1 |
2011 |
| Drug |
second phase of induction |
1 |
2017 |
| Drug |
sel120 |
1 |
2019 |
| Drug |
sel24 |
1 |
2016 |
| Drug |
sel24/men1703 |
1 |
2016 |
| Biological |
selected natural killer cells collected from apheresis products |
1 |
2011 |
| Other |
selection |
1 |
2012 |
| Biological |
selection with clinimacs device |
1 |
2005 |
| Device |
selection) |
1 |
2013 |
| Other |
selection. |
1 |
2012 |
| Behavioral |
self directed weight loss |
1 |
2014 |
| Drug |
semaxanib |
1 |
2000 |
| Drug |
sequential packaging (set) |
1 |
2016 |
| Drug |
sertraline |
1 |
2016 |
| Drug |
sgi-110 |
1 |
2014 |
| Drug |
sgi-110 (guadecitabine) |
1 |
2015 |
| Drug |
sgi-110 administration |
1 |
2014 |
| Drug |
sgn-40 (anti-hucd40 mab) |
1 |
2006 |
| Drug |
sgn-cd19a |
1 |
2013 |
| Device |
sham |
1 |
2014 |
| Device |
sham tdcs |
1 |
2019 |
| Device |
sham treatment |
1 |
2019 |
| Dietary Supplement |
sheng-yu-tang |
1 |
2015 |
| Drug |
shingrix vaccine |
1 |
2018 |
| Biological |
silk |
1 |
2019 |
| Dietary Supplement |
silymarin |
1 |
2003 |
| Biological |
single dose of cnct19 |
1 |
2020 |
| Biological |
single dose of ctl019 |
1 |
2015 |
| Radiation |
single dose total body irradiation |
1 |
2016 |
| Biological |
single ft1050 treated ucb unit |
1 |
2012 |
| Procedure |
single photon emission computed tomography |
1 |
2017 |
| Biological |
single umbilical cord blood unit transplant |
1 |
2006 |
| Drug |
sirolimus (sir) |
1 |
2017 |
| Drug |
sirolimus/methotrexate |
1 |
2010 |
| Drug |
ski-606 (bosutinib) |
1 |
2008 |
| Drug |
ski-g-801 |
1 |
2018 |
| Behavioral |
sleep hygiene |
1 |
2014 |
| Behavioral |
sleep hygiene/relaxation education |
1 |
2014 |
| Drug |
sndx-5613 |
1 |
2019 |
| Drug |
sodium chloride solution 0.9% |
1 |
2012 |
| Drug |
sodium ferric gluconate complex in sucrose |
1 |
2008 |
| Drug |
sodium salicylate |
1 |
2000 |
| Device |
solex 300i stem cell selection |
1 |
2006 |
| Drug |
solumedrol |
1 |
2008 |
| Drug |
sonidegib |
1 |
2014 |
| Drug |
sorafenib-vorinostat |
1 |
2009 |
| Drug |
sorafenib, vorinostat |
1 |
2012 |
| Drug |
sorafenib, vorinostat/bortezomib |
1 |
2012 |
| Drug |
sotatercept |
1 |
2012 |
| Drug |
spc2996 |
1 |
2005 |
| Biological |
specificity cd38 car-t cells |
1 |
2018 |
| Other |
specimen collection |
1 |
2018 |
| Drug |
spectrilaâ® |
1 |
2017 |
| Other |
sport therapy |
1 |
2019 |
| Dietary Supplement |
st. john’s wort |
1 |
2000 |
| Drug |
sta-9090 (ganetespib) |
1 |
2009 |
| Other |
staining method |
1 |
2003 |
| Drug |
standard chemotherapy (7 |
1 |
2009 |
| Drug |
standard chemotherapy (7/3 scheme): daunorubicin, cytarabine |
1 |
2009 |
| Drug |
standard chemotherapy / imatinib |
1 |
2006 |
| Drug |
standard combination chemotherapy |
1 |
2014 |
| Drug |
standard consolidation therapy |
1 |
2017 |
| Drug |
standard dose cytarabine for induction |
1 |
2014 |
| Drug |
standard dose trivalent inactivated influenza vaccine |
1 |
2010 |
| Drug |
standard induction therapy |
1 |
2017 |
| Dietary Supplement |
standard vitamin d3 supplementation |
1 |
2017 |
| Drug |
stat inhibitor opb-111077 |
1 |
2017 |
| Procedure |
stem cell transfusion |
1 |
2003 |
| Procedure |
stem cell transplantation (sct) |
1 |
2020 |
| Drug |
stem cells |
1 |
2008 |
| Drug |
stemexâ® |
1 |
2007 |
| Procedure |
steroid therapy, hematopoietic stem cell transplantation |
1 |
2005 |
| Drug |
sti571 |
1 |
2007 |
| Drug |
sti571 (400 mg |
1 |
2007 |
| Drug |
sti571 (400 mg/day;/800 mg/day) |
1 |
2007 |
| Other |
stopping treatment with tki |
1 |
2012 |
| Other |
stroma cells |
1 |
1999 |
| Other |
structured education dvd |
1 |
2015 |
| Other |
structured education dvd / verbal teaching |
1 |
2015 |
| Other |
study of socioeconomic |
1 |
2008 |
| Other |
study of socioeconomic/demographic variables |
1 |
2008 |
| Drug |
subcutaneous (sc) azacitidine |
1 |
2007 |
| Drug |
succimer |
1 |
2018 |
| Drug |
sunitinib |
1 |
2019 |
| Drug |
supersaturated calcium phosphate rinse |
1 |
2011 |
| Behavioral |
support |
1 |
2009 |
| Other |
supportive |
1 |
2015 |
| Other |
supportive /palliative care intervention |
1 |
2015 |
| Other |
surface expression of functional biomarkers of the nk cell |
1 |
2009 |
| Other |
surveillance |
1 |
2017 |
| Drug |
sy-1425 (tamibarotene) |
1 |
2016 |
| Drug |
syb l-0501 |
1 |
2013 |
| Procedure |
syngeneic bone marrow transplantation |
1 |
1999 |
| Biological |
syngeneic pbtls |
1 |
2008 |
| Biological |
synthetic tumor-specific breakpoint peptide vaccine |
1 |
2005 |
| Drug |
systematic chemotherapy |
1 |
2005 |
| Drug |
systematic chemotherapy/antibodies |
1 |
2005 |
| Drug |
systemic chemotherapy |
1 |
2005 |
| Drug |
systemic chemotherapy/antibodies |
1 |
2005 |
| Biological |
t-allo10 |
1 |
2017 |
| Biological |
t-cell antigen presenting cells expressing truncated cd19 (t-apc) |
1 |
2017 |
| Other |
t-cell depleted |
1 |
2009 |
| Procedure |
t-cell depleted hsct from a related, haploidentical donor |
1 |
2016 |
| Other |
t-cell depleted/t-cell replete strategies |
1 |
2009 |
| Procedure |
t-cell replete hsct from a related, haploidentical donor |
1 |
2016 |
| Other |
t-cell replete pbpc allograft |
1 |
1999 |
| Other |
t-cell replete strategies |
1 |
2009 |
| Biological |
t-lymphocytes |
1 |
2017 |
| Device |
t cell |
1 |
2019 |
| Biological |
t cell-depleted donor lymphocyte infusion |
1 |
2015 |
| Biological |
t cells |
1 |
2012 |
| Drug |
tablet pyridoxine hydrochlorid |
1 |
2018 |
| Drug |
tacrolimus (arm with methotrexate) |
1 |
2014 |
| Drug |
tacrolimus (arm with mmf |
1 |
2014 |
| Drug |
tacrolimus (arm with mmf/cyclophosphamide) |
1 |
2014 |
| Drug |
tacrolimus (tac) |
1 |
2018 |
| Biological |
tafasitamab |
1 |
2015 |
| Drug |
tak-659 |
1 |
2014 |
| Drug |
tak-901 |
1 |
2008 |
| Drug |
talabostat mesylate (pt-100) tablets |
1 |
2004 |
| Drug |
talacotuzumab 9 mg |
1 |
2015 |
| Drug |
talacotuzumab 9 mg/kg |
1 |
2015 |
| Drug |
tamibarotene |
1 |
2007 |
| Radiation |
targeted radiotherapy |
1 |
2012 |
| Drug |
tasigna |
1 |
2011 |
| Drug |
tazobactam sodium |
1 |
1999 |
| Biological |
tbi-1501 |
1 |
2017 |
| Procedure |
tbi regime |
1 |
2015 |
| Drug |
tbi, systemic chemotherapy |
1 |
2005 |
| Drug |
tbi, systemic chemotherapy/antibodies as follows: |
1 |
2005 |
| Drug |
tbi/cy/vp-16 |
1 |
2011 |
| Drug |
tc-110 t cells |
1 |
2020 |
| Biological |
tcon |
1 |
2019 |
| Biological |
tcr alfa beta t cell depletion |
1 |
2012 |
| Biological |
tcrî± |
1 |
2019 |
| Biological |
tcrî±/î²/ |
1 |
2019 |
| Procedure |
tcrî±î² |
1 |
2015 |
| Procedure |
tcrî±î²//cd19/ depleted haploidentical hsct |
1 |
2015 |
| Biological |
tem1 monoclonal antibody morab-004 |
1 |
2012 |
| Drug |
tenalisib |
1 |
2019 |
| Biological |
tetanus |
1 |
2012 |
| Biological |
tetanus-cmv fusion peptide vaccine |
1 |
2012 |
| Biological |
tetanus toxoid |
1 |
2015 |
| Drug |
tetrahydrouridine |
1 |
2009 |
| Drug |
tevagastrim |
1 |
2012 |
| Biological |
tg-1501 |
1 |
2015 |
| Drug |
tg02 citrate |
1 |
2012 |
| Drug |
tgr-1202 / obinutuzumab / chlorambucil |
1 |
2014 |
| Drug |
tgr-1202 / ublituximab |
1 |
2017 |
| Drug |
th-302 |
1 |
2010 |
| Drug |
th2 cells |
1 |
1999 |
| Drug |
th2 cells in allo hsctt |
1 |
1999 |
| Drug |
theophyllin |
1 |
2005 |
| Drug |
theophylline |
1 |
1999 |
| Biological |
therapeutic autologous dendritic cells |
1 |
2009 |
| Biological |
therapeutic platelet transfusion |
1 |
2007 |
| Procedure |
therapeutic touch |
1 |
2006 |
| Drug |
thio tepa |
1 |
2019 |
| Drug |
thioguanine (oral) |
1 |
2016 |
| Drug |
thioplexâ® |
1 |
2007 |
| Drug |
thioridazine |
1 |
2014 |
| Drug |
thiotepa in conditioning before transplantation |
1 |
2009 |
| Biological |
third-generation anti-cd123 car-t cells |
1 |
2019 |
| Procedure |
three-dimensional spoiled gradient mri |
1 |
2015 |
| Drug |
thymoglobulin (atg) |
1 |
2009 |
| Biological |
thymoglobulin [anti-thymocyte globulin (rabbit)] |
1 |
2004 |
| Drug |
tigecycline |
1 |
2011 |
| Behavioral |
timed get-up |
1 |
2007 |
| Behavioral |
timed get-up/go test (tgug). |
1 |
2007 |
| Drug |
tioguanin |
1 |
2018 |
| Drug |
tipifarnib (r115777) |
1 |
2006 |
| Drug |
tipifarnib;zarnestra; r115777 |
1 |
2004 |
| Biological |
tisagenlecleucel |
1 |
2015 |
| Other |
titrated pain management |
1 |
2008 |
| Drug |
tj011133 |
1 |
2019 |
| Drug |
tki |
1 |
2016 |
| Other |
tki discontinuation |
1 |
2016 |
| Drug |
tm123 (imp) |
1 |
2020 |
| Drug |
tms |
1 |
2007 |
| Biological |
tn lymphocytes |
1 |
2016 |
| Drug |
topotecan, dexamethasone, vincristine |
1 |
2005 |
| Combination Product |
tositumomab |
1 |
2007 |
| Combination Product |
tositumomab/iodine i 131 tositumomab |
1 |
2007 |
| Radiation |
total body irradiation (8gy) |
1 |
2019 |
| Radiation |
total body irradiation (tbi) 200cgy on day -1 |
1 |
2016 |
| Radiation |
total body irradiation (tbi) 200cgy twice a day on days -3, -2, -1 |
1 |
2016 |
| Radiation |
total body irradiation 1200 cgy |
1 |
2016 |
| Radiation |
total body irradiation 200 cgy |
1 |
2016 |
| Radiation |
total body radiation |
1 |
2011 |
| Radiation |
total lymphoid irradiation |
1 |
2007 |
| Radiation |
total lymphoid irradiation (tli) |
1 |
2018 |
| Radiation |
total marrow irradiation (tmi) |
1 |
2018 |
| Radiation |
total nodal irradiation |
1 |
2015 |
| Device |
transcranial direct current stimulation (tdcs) |
1 |
2014 |
| Drug |
transfusion graft |
1 |
2016 |
| Procedure |
transplant |
1 |
2007 |
| Drug |
transplants from 8 |
1 |
2012 |
| Drug |
transplants from 8/8-matched unrelated donors |
1 |
2012 |
| Drug |
transplants from family-mismatched |
1 |
2012 |
| Drug |
transplants from family-mismatched/haploidentical donors |
1 |
2012 |
| Drug |
traumeel s |
1 |
2004 |
| Drug |
treatment choice (tc) |
1 |
2016 |
| Biological |
trebananib |
1 |
2012 |
| Biological |
treg |
1 |
2019 |
| Biological |
treg infusion |
1 |
2008 |
| Biological |
treggraft |
1 |
2019 |
| Drug |
tretinoin/arsenic trioxide |
1 |
2011 |
| Drug |
triciribine |
1 |
2008 |
| Drug |
trimethoprim-sulfamethoxazole |
1 |
2003 |
| Drug |
trimetrexate glucuronate |
1 |
1999 |
| Drug |
triple intrathecal therapy |
1 |
2013 |
| Drug |
triple intrathecal therapy (mtx, cytarabine, hydrocortisone) |
1 |
2005 |
| Drug |
triple intrathecal therapy (tit) |
1 |
2008 |
| Drug |
triple it therapy |
1 |
2007 |
| Drug |
troxacitabine |
1 |
2001 |
| Drug |
tru-016 |
1 |
2010 |
| Drug |
tru-016 (anti-cd37 protein therapeutic) |
1 |
2008 |
| Biological |
tru-016 10-20 mg |
1 |
2012 |
| Biological |
tru-016 10-20 mg/kg / bendamustine |
1 |
2012 |
| Biological |
tru-016 10-20 mg/kg / ibrutinib |
1 |
2012 |
| Biological |
tru-016 20 mg |
1 |
2012 |
| Biological |
tru-016 20 mg/kg / obinutuzumab |
1 |
2012 |
| Biological |
tru-016 6-20 mg |
1 |
2012 |
| Biological |
tru-016 6-20 mg/kg / idelalisib / rituximab |
1 |
2012 |
| Drug |
tru-016/bendamustine |
1 |
2010 |
| Biological |
tslpr |
1 |
2019 |
| Behavioral |
two-step remission induction |
1 |
2006 |
| Behavioral |
two-step remission induction/risk-oriented consolidation |
1 |
2006 |
| Drug |
txa127 1000 mcg |
1 |
2011 |
| Drug |
txa127 1000 mcg/kg/day |
1 |
2011 |
| Drug |
txa127 300 mcg |
1 |
2011 |
| Drug |
txa127 300 mcg/kg/day |
1 |
2011 |
| Drug |
tylenol |
1 |
2009 |
| Drug |
tyrosine kinase inhibitor |
1 |
2019 |
| Drug |
tyrosine kinase inhibitor (tki) |
1 |
2011 |
| Drug |
tyrosine kinase inhibitor (tkis) |
1 |
2018 |
| Biological |
ucart019 |
1 |
2017 |
| Biological |
ucart123 |
1 |
2017 |
| Biological |
ucart22 |
1 |
2019 |
| Biological |
uld il-2 |
1 |
2014 |
| Genetic |
umbilical cord blood (ucb) |
1 |
2013 |
| Biological |
umbilical cord blood cell infusion |
1 |
2016 |
| Procedure |
umbilical cord blood transfusion |
1 |
2013 |
| Biological |
umbilical cord blood unit (cbu) |
1 |
2015 |
| Drug |
unicar02-t (imp) |
1 |
2020 |
| Biological |
universal dual specificity cd19 |
1 |
2018 |
| Biological |
universal dual specificity cd19/cd20/cd22 car-t cells |
1 |
2018 |
| Biological |
unmanipulated umbilical cord blood (ucb) |
1 |
2018 |
| Biological |
unrelated bone marrow cells |
1 |
2016 |
| Biological |
unrelated cord blood |
1 |
2019 |
| Other |
unrelated donor transplant. |
1 |
2012 |
| Drug |
up-front allogeneic hematopoietic stem cell transplantation (hsct) |
1 |
2019 |
| Biological |
us-atg-f |
1 |
2011 |
| Combination Product |
usual clinical practice |
1 |
2018 |
| Procedure |
uv light therapy |
1 |
2003 |
| Drug |
valacyclovir |
1 |
2007 |
| Drug |
valemetostat tosylate |
1 |
2019 |
| Drug |
valproate |
1 |
2014 |
| Drug |
valproic acid (vpa) |
1 |
2006 |
| Drug |
vancomycin |
1 |
1999 |
| Drug |
vay736 |
1 |
2018 |
| Drug |
vcap |
1 |
2010 |
| Drug |
vcap-amp-vecp with g-csf |
1 |
2005 |
| Drug |
vcap-amp-vecp with g-csf/intrathecal prophylaxis |
1 |
2005 |
| Drug |
vcap/amp/vecp(mlsg15) |
1 |
2010 |
| Biological |
vcl-cb01 |
1 |
2006 |
| Drug |
vcr |
1 |
2014 |
| Drug |
vecp(mlsg15) |
1 |
2010 |
| Biological |
veltuzumab |
1 |
2007 |
| Drug |
ven) |
1 |
2019 |
| Drug |
venetoclax (part 2 - recruiting) |
1 |
2010 |
| Drug |
venetoclax 12 cycles |
1 |
2017 |
| Drug |
venetoclax 15 cycles |
1 |
2017 |
| Drug |
venetoclax/ibrutinib (i/ven) |
1 |
2019 |
| Other |
verbal teaching |
1 |
2015 |
| Drug |
vial |
1 |
2010 |
| Drug |
vidaza/valproic acid |
1 |
2014 |
| Drug |
vidazaâ® |
1 |
2011 |
| Drug |
vinblastine |
1 |
2012 |
| Drug |
vincristine / vindesine |
1 |
2005 |
| Drug |
vincristine sulfate liposome |
1 |
2017 |
| Drug |
vincristine sulfate liposomes injection |
1 |
2005 |
| Drug |
vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-c |
1 |
2012 |
| Drug |
vincristine/vindesine |
1 |
2005 |
| Drug |
vinorelbine ditartrate |
1 |
1999 |
| Drug |
vinorelbine tartrate |
1 |
2007 |
| Other |
virtual reality |
1 |
2019 |
| Genetic |
virus specific t cells |
1 |
2009 |
| Other |
vital signs |
1 |
2008 |
| Drug |
vitamin b complex |
1 |
2018 |
| Dietary Supplement |
vitamin d/calcium citrate |
1 |
2011 |
| Dietary Supplement |
vitamin e |
1 |
1999 |
| Drug |
vls-101 schedule 1 |
1 |
2019 |
| Drug |
vls-101 schedule 2 |
1 |
2019 |
| Drug |
vls-101 schedule 3 |
1 |
2019 |
| Drug |
voreloxin injection |
1 |
2007 |
| Drug |
voreloxin injection/cytarabine |
1 |
2007 |
| Drug |
voruciclib |
1 |
2018 |
| Drug |
vosaroxin / cytarabine |
1 |
2010 |
| Drug |
vpa |
1 |
2009 |
| Drug |
vsli |
1 |
2011 |
| Drug |
w |
1 |
2015 |
| Other |
waist circumference, |
1 |
2014 |
| Behavioral |
wait list |
1 |
2008 |
| Behavioral |
website through healthways at hopkins |
1 |
2014 |
| Drug |
wee1 inhibitor azd1775 |
1 |
2016 |
| Genetic |
welgenaleucel |
1 |
2019 |
| Radiation |
whole-brain radiation therapy |
1 |
2010 |
| Other |
withdrawal of immunosuppression |
1 |
2009 |
| Other |
withdrawal of immunosuppression/donor lymphocyte infusion |
1 |
2009 |
| Behavioral |
writing a (experimental informative writing) |
1 |
2008 |
| Behavioral |
writing b (experimental noninformative writing) |
1 |
2008 |
| Behavioral |
writing c (control informative writing) |
1 |
2008 |
| Behavioral |
writing d (control noninformative writing) |
1 |
2008 |
| Biological |
wt-1 analog peptide vaccine |
1 |
2006 |
| Procedure |
wt 1 testing |
1 |
2005 |
| Biological |
wt1 |
1 |
2015 |
| Biological |
wt1-sensitized allogeneic t-lymphocytes |
1 |
2011 |
| Biological |
wt1-sensitized t cells |
1 |
2008 |
| Biological |
wt1 126-134 peptide vaccine |
1 |
2012 |
| Drug |
wt1 peptide-pulsed dendritic cells |
1 |
2009 |
| Drug |
wt1 peptides |
1 |
2009 |
| Genetic |
wt1 tcr-transduced t cells |
1 |
2012 |
| Biological |
wt1/prame vaccination |
1 |
2015 |
| Biological |
wt1:126-134 |
1 |
2007 |
| Biological |
xmab13676 |
1 |
2016 |
| Biological |
xmab14045 |
1 |
2016 |
| Biological |
xmab5574 |
1 |
2010 |
| Genetic |
xyf19 car-t cell |
1 |
2019 |
| Other |
yttrium-90 labelled monoclonal antibody against cd66 |
1 |
2019 |
| Drug |
yttrium-90 radiolabeled anti-tac antibody |
1 |
1999 |
| Radiation |
yttrium y 90 daclizumab |
1 |
2001 |
| Radiation |
yttrium y 90 ibritumomab tiuxetan |
1 |
2007 |
| Radiation |
yttrium y 90 monoclonal antibody m195 |
1 |
2000 |
| Drug |
zarnestra (r115777) |
1 |
2002 |
| Drug |
zarnestra, tipifarnib, r115777 |
1 |
2002 |
| Drug |
zavedos |
1 |
2009 |
| Drug |
zevalin radioimmunotherapy |
1 |
2002 |
| Drug |
zidovudine |
1 |
2016 |
| Drug |
zinc sulfate 50 mg tab |
1 |
2020 |
| Drug |
zio-101 (darinaparsin) |
1 |
2007 |
| Drug |
zoledronate |
1 |
2015 |
| Drug |
zolinza |
1 |
2011 |
| Drug |
zolinza/vorinostat |
1 |
2011 |
| Drug |
zosuquidar trihydrochloride |
1 |
2002 |